US20110320167A1 - Method and System for Evaluating Analyte Sensor Response Characteristics - Google Patents

Method and System for Evaluating Analyte Sensor Response Characteristics Download PDF

Info

Publication number
US20110320167A1
US20110320167A1 US13/166,797 US201113166797A US2011320167A1 US 20110320167 A1 US20110320167 A1 US 20110320167A1 US 201113166797 A US201113166797 A US 201113166797A US 2011320167 A1 US2011320167 A1 US 2011320167A1
Authority
US
United States
Prior art keywords
data range
values
best fit
windows
range windows
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US13/166,797
Other versions
US8635046B2 (en
Inventor
Erwin Satrya Budiman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Diabetes Care Inc
Original Assignee
Abbott Diabetes Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Diabetes Care Inc filed Critical Abbott Diabetes Care Inc
Priority to US13/166,797 priority Critical patent/US8635046B2/en
Publication of US20110320167A1 publication Critical patent/US20110320167A1/en
Assigned to ABBOTT DIABETES CARE INC. reassignment ABBOTT DIABETES CARE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BUDIMAN, ERWIN SATRYA
Priority to US14/158,662 priority patent/US20140136145A1/en
Application granted granted Critical
Publication of US8635046B2 publication Critical patent/US8635046B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10Complex mathematical operations
    • G06F17/18Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1495Calibrating or testing of in-vivo probes

Definitions

  • Benefits of a closed loop control system for treating diabetic conditions with monitoring glucose levels and adjusting delivery rate of insulin are well known.
  • Such systems referred to as artificial pancreas, model healthy pancreas which, when functioning normally, produces insulin (by the beta cells ( ⁇ -cells)) to counteract the rise in glucose levels in the blood stream.
  • beta cells beta cells
  • Type-1 diabetes mellitus condition exists when the beta cells in the pancreas either die or are unable to produce sufficient amount of insulin naturally in response to the elevated glucose levels.
  • Type-1 diabetes Common treatment of Type-1 diabetes is the use of insulin pumps that are programmed to continuous delivery insulin to the body through an infusion set.
  • insulin pumps to treat Type-2 diabetes (where the beta cells in the pancreas do produce insulin, but an inadequate quantity) is also becoming more prevalent.
  • Such insulin delivery devices are preprogrammed with delivery rates such as basal profiles which are tailored to each user, and configured to provide the needed insulin to the user.
  • continuous glucose monitoring systems have been developed to provide real time monitoring of fluctuation in glucose levels.
  • One example is the FreeStyle Navigator® Continuous Glucose Monitoring System available from Abbott Diabetes Care Inc., of Alameda, Calif.
  • the use of such glucose monitoring systems provides the user with real time glucose level information.
  • diabetics are able to determine when insulin is needed to lower glucose levels or when additional glucose is needed to raise the level of glucose.
  • Using a continuous glucose monitoring system in conjunction with an insulin pump can be an effective treatment tool for individuals with Type-1 or severe Type-2 diabetic condition to maintain their blood sugar levels at a physiologically desirable range.
  • characteristics of the continuous glucose monitoring system particularly the continuous glucose sensor of the system, must be evaluated and accurate. Evaluation of characteristics, such as linearity and lag, associated with continuous glucose sensors can impact glucose control errors and previous methods of evaluating such characteristics, such as linearity, can be confounded by lag, noise and apparent nonlinearities due to data distribution.
  • a method for evaluating characteristics of a continuous analyte sensor in one aspect of the present disclosure includes receiving a plurality of continuous analyte sensor values for corresponding reference analyte values, calculating a rate of change value for the continuous analyte sensor values, defining a plurality of data range windows of the reference analyte values, evaluating the corresponding continuous analyte sensor values, the rate of change values, the reference analyte values, and/or a plurality of corresponding difference values for the plurality of data range windows, and determining a best fit based on the evaluation of the plurality of data range windows is provided.
  • the difference value is the difference between the continuous analyte sensor value and the corresponding reference analyte value and determining the best fit includes determining a least-squares line or relationship based on a graphical representation of the rate of change of glucose values and the difference values for each of the plurality of data range windows.
  • Certain aspects of the present disclosure include determining a slope and an intercept of the least-squares line for each of the plurality of data range windows and determining a best fit function based on a graphical representation of the intercepts of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, where the best fit function corresponds to a linearity characteristic of the continuous analyte sensor and determining a best fit function based on a graphical representation of the slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, where the best fit function corresponds to a lag characteristic of the continuous analyte sensor are provided.
  • FIG. 1 is a block diagram illustrating a system for evaluating characteristics of a sensor in one or more embodiments of the present disclosure
  • FIG. 2 is a flow chart illustrating a method for evaluating characteristics of a sensor response in one or more embodiments of the present disclosure
  • FIG. 3 is a plot illustrating a sample data set of continuous glucose values and corresponding reference blood glucose values taken at time instances m;
  • FIG. 4 is a plot illustrating the sample data set of FIG. 3 with indication of excluded ranges of reference blood glucose values
  • FIG. 5 is a plot illustrating a range window of 70 mg/dL to 100 mg/dL of reference glucose values G b (m) for the sample data set of FIG. 3 ;
  • FIG. 6 illustrates a best fit line for the range of 70 mg/dL to 100 mg/dL of reference glucose values G b (m) for the sample data set of FIG. 3 ;
  • FIG. 7 illustrates a weighted best fit line for the intercepts of the ranges G bc (r) for the sample data set of FIG. 3 ;
  • FIG. 8 illustrates a corrected slope value over the ranges G bc (r) for the sample data set of FIG. 3 .
  • analyte sensor in some embodiments, may be part of an analyte monitoring system, such as a glucose monitoring system, such as a continuous glucose monitoring system.
  • analyte sensors and analyte monitoring systems to which the disclosed methods may be applied can be found in, for example, among others, U.S. Pat. Nos. 6,103,033, 6,134,461, 6,175,752, 6,284,478 and 6,560,471 and in U.S.
  • FIG. 1 is a block diagram illustrating a system for evaluating characteristics of an analyte sensor in one or more embodiments of the present disclosure.
  • a system 100 for evaluating characteristics of an analyte sensor includes an analyte monitoring device 110 , the analyte monitoring device 110 including an analyte sensor 111 for which characteristics are to be evaluated, and a transmitter module 112 to enable communication with one or more other devices.
  • the system 100 may also include a receiver unit 120 in data communication with the analyte monitoring device 110 and a data processing unit 130 , such as a computer or other microprocessor driven device.
  • system 100 include a reference blood glucose meter, such as a conventional in vitro blood glucose meter 140 .
  • a reference blood glucose meter such as a conventional in vitro blood glucose meter 140 .
  • Example analyte monitoring systems can be found in, among others, U.S. Pat. No. 6,175,752, the disclosure of which is incorporated herein by reference for all purposes.
  • the analyte sensor 111 of analyte monitoring device 110 is a glucose sensor configured for the continuous monitoring of glucose level fluctuation in a patient or fluid sample.
  • the sensor may be configured to monitor other analytes, drugs, or chemicals, and may be configured for semi-continuous or periodic measurement.
  • the sensor 111 is in communication with a transmitter module 112 of the analyte monitoring device.
  • the transmitter module 112 is configured to transmit wirelessly or via a wired connection, data signals received from the analyte sensor 111 corresponding to the measured analyte level.
  • the analyte monitoring device 110 includes other components (not shown) in addition to the analyte sensor 111 and transmitter module 112 , including, but not limited to, one or more processing units, one or more memory units, one or more input and/or output units, a temperature detection module, and a power supply.
  • the components of the analyte monitoring device 110 may be integrated into a single housing or in other embodiments may be in two or more separate housings in data communication with one another.
  • the analyte monitoring device 110 is in communication with a receiver unit 120 via the transmitter module 112 .
  • the receiver unit 120 is configured to process and/or display data received from the analyte monitoring device.
  • the receiver unit 120 in some embodiments, is in communication with a data processing unit 130 , which may be, among others, a personal computer or other microprocessor driven device.
  • the data processing unit 130 may be configured to further process data received from the analyte monitoring device 110 via the receiver unit 120 , or directly from the analyte monitoring device via a communication link 150 .
  • the data processing unit 130 is located at a remote location separated from the analyte monitoring device 110 and receiver unit 120 and data is transferred to the data processing unit 130 via a network, such as a local area network or a wide area network via the internet.
  • the data processing unit 130 may further be in communication with a reference blood glucose meter 140 to receive reference values for use in data processing and evaluation.
  • reference values may be obtained from other reference devices, which may be specifically chosen based upon the desired analyte, drug, or chemical to be analyzed and evaluated.
  • Each element of the system 100 of FIG. 1 may be individual units, or alternatively, one or more or all of the elements may be integrated into single integrated unit.
  • the reference blood glucose meter 140 may be integrated into the receiver unit 130 .
  • each the data processing unit 130 and/or the receiver unit 120 or the analyte monitoring device 110 may be configured to process data received from the sensor 111 .
  • Processing data from the sensor 111 may include, among others, evaluating characteristics of the sensor 111 , such as calculating lag and/or linearity of the sensor response, as will be described in further detail in conjunction with the flow chart of FIG. 2 below.
  • FIG. 2 is a flow chart illustrating a method for evaluating characteristics of a sensor response in one or more embodiments of the present disclosure.
  • a sensor such as sensor 111 of FIG. 1
  • a continuous glucose sensor for which the characteristics, including lag and linearity characteristics are to be evaluated.
  • the evaluation of the sensor characteristics is carried out by the data processing unit 130 of the evaluation system 100 .
  • the evaluation is carried out by the receiver unit 120 .
  • the evaluation is carried out by the analyte monitoring device 110 .
  • the evaluation is carried out by a combination of the analyte monitoring device 110 , receiver unit 120 , and/or the data processing unit 130 .
  • the rate of change of a measured analyte (e.g., glucose) level as measured by the continuous glucose sensor, such as analyte sensor 111 of system 100 of FIG. 1 , at a given time k, is determined ( 210 ).
  • the rate of change at time k, V i (k) can be calculated, in one embodiment, by choosing or selecting a measurement window with half window N hr , such that the analyte level values as measured by the continuous glucose sensor G i (k), in the window are collected ⁇ G i (k ⁇ N hr ), . . . G i (k ⁇ 1), G i (k), G i (k+1), . . . G i (k+N hr ) ⁇ , and an average rate of change of the analyte level is computed or determined from these points.
  • the half window N hr is between 1 and 15 minutes with a measurement window of between 3 and 31 minutes, however, it is to be appreciated that the window could be less than 3 minutes or greater than 31 minutes.
  • the measurement window duration needed for an accurate rate calculation may be based on the sensor type, such that, for example, a continuous, substantially continuous, or semi-continuous sensor which outputs measured analyte levels at a faster rate than an intermittent or periodic sensor, may require a shorter measurement window duration to obtain enough data points for an accurate rate of change calculation, while a periodic sensor may require a longer measurement window duration in order to obtain enough data points for an accurate rate of change calculation.
  • the rate of change at time k, V i (k) can be calculated from the slope of a best fit line, such as a least-squares error line, of the points ⁇ G i (k ⁇ N hr ), . . . G i (k ⁇ 1), G i (k), G i (k+1), . . . G i (k+N hr ) ⁇ .
  • a best fit line such as a least-squares error line
  • the rate of change at time k, V i (k), is calculated by taking two neighboring points G i (k ⁇ N hr ) and G i (k+N hr ), that are half-window N hr samples before and after the glucose level value G i (k), respectively, and then computing the slope between these two neighboring points.
  • the rate of change values V i (m), and the continuous glucose sensor values G i (m) at time m are matched with reference blood glucose values G b (m), at time m ( 220 ). Matching the rate of change value and continuous glucose sensor value and the reference blood glucose value at time m generates triplets ⁇ G b (m), G i (m), V i (m) ⁇ .
  • Reference blood glucose values can be obtained in a variety of ways including measuring a blood glucose value in vitro by applying a blood sample to a test strip and measuring the blood glucose value with a conventional blood glucose monitor, such as the reference blood glucose meter 140 of FIG. 1 .
  • FIG. 3 is a plot illustrating a sample data set of continuous glucose values and corresponding reference blood glucose values taken at time instances m. For each of these pairs of matched continuous glucose sensor values G i (m), and reference blood glucose values G b (m), a corresponding continuous glucose rate of change value V i (m), also exists.
  • the triplets are evaluated to determine which triplets are considered reliable data and which triplets are to be excluded due to unreliability ( 230 ).
  • the evaluation of the triplets may be based on stratified evaluations of the triplet data taken over predetermined ranges of reference blood glucose values G b , i.e., wherein each of the predetermined ranges of reference blood glucose values are evaluated individually for the evaluation of the triplets. As such, the evaluations are performed individually on a plurality of groups of reference blood glucose values in order to determine the final result.
  • evaluation of each individual range may be utilized for various weighted analysis as described in further detail below. From within each range of reference blood glucose values, the continuous glucose values are evaluated to determine if upper limit or lower limit clipping has occurred. In some embodiments, in evaluated ranges of reference blood glucose values where a significant number of triplets include continuous glucose sensor values G i that are clipped at the upper or lower range, these ranges of reference blood glucose values G b are excluded from the data set. Upper and lower clipping limits may be determined based upon the particular sensor being evaluated. For example, the lower clipping limit, in one sensor embodiment, may be 20 mg/dL and the upper clipping limit may be 500 mg/dL.
  • the excluded of ranges of reference blood glucose values where a significant number of continuous glucose sensor values G i are clipped can be replaced by the statistical method of left and right censoring.
  • the sample data set of FIG. 3 was evaluated for ranges of reference blood glucose values where substantial clipping occurred and ranges of reference blood glucose values where insufficient continuous glucose data points were present.
  • the result of the evaluation of the sample data set was reference blood glucose values G b , that fell between 70 mg/dL and 400 mg/dL were evaluated as reliable and the ranges of reference blood glucose values below 70 mg/dL and above 400 mg/dL were excluded from the data set.
  • data range windows of the reference blood glucose values G b are defined ( 250 ) based on the reference glucose values G b that were not excluded due to unreliability because of clipping and/or lack of available data points.
  • these data range windows of reference blood glucose values G b are used for stratified analysis of the continuous glucose data when compared with the corresponding reference blood glucose data.
  • the stratified analysis allows for individual analysis and evaluation of the continuous glucose data for each of the corresponding data range windows of reference blood glucose values. As such, the evaluations are performed individually on a plurality of groups of reference blood glucose values in order to determine the final result.
  • evaluation of each individual data range window may be utilized for various weighted analysis as described in further detail below.
  • the data range windows may be defined based on the overall data range of values, the number of continuous glucose data values available, or other factors. In one embodiment, the data range windows may be defined as 30 mg/dL data range windows beginning at the lowest non-excluded limit of the reference glucose values G b .
  • the first data range window of the sample data set of FIGS. 3 and 4 may be from 70 mg/dL to 100 mg/dL.
  • the next data range window may be from 100 mg/dL to 130 mg/dL and so on until the ranges reach the upper non-excluded limit of reference glucose value G b .
  • the data range windows may overlap, such that a first data range window is from 70 mg/dL to 100 mg/dL and the next data range window is from 80 mg/dL to 110 mg/dL and so on until the upper non-excluded limit of the reference glucose values G b is reached.
  • each data range window of the reference glucose values G b there is a center reference blood glucose value, G bc (r).
  • G bc (r) the data range window from 70 mg/dL to 100 mg/dL would have a center reference blood glucose value G bc (r) of 85 mg/dL.
  • the data range window may be defined as 30 mg/dL, and data range center reference blood glucose value G bc (r) values are at 85, 95, . . . , 375 mg/dL. This also defines the left edges (lower range limit), G bl (r) to 70, 80, . . . , 360 mg/dL and the right edges (upper range limit), G br (r) to 100, 110, . . . , 390 mg/dL.
  • the decision for the distance between the centers of the data range windows, and the amount of overlap may depend on the tradeoff between desired data range resolution (e.g.
  • the quadruplets of ⁇ G b (m), G i (m), V i (m), ⁇ G(m) ⁇ that fall within each data range window are determined ( 260 ).
  • the quadruplets with reference blood glucose value at time m G b (m) values that are no smaller than the lower range limit, G bl and no greater than the upper range limit G br are collected for the particular data range window.
  • a best fit line of the difference value ⁇ G(m) compared to each rate of change value V i (m) for the data range window is determined ( 270 ).
  • the best fit line is calculated by setting the rate of change values V i (m) to be on the x-axis and the corresponding difference value, ⁇ G(m), to be on the y-axis of a scatter plot for a particular data range window and performing a least-squares error fit of a line between on the points.
  • the least-squares analysis minimizes the sum of the squared residuals of the points and calculates the best fit line of the points.
  • the intercept I(r) and slope S(r) of the particular data range window can be calculated. Further, the number of quadruplets that fall within the data range window N(r), can be determined. It will be appreciated by one skilled in the art that the best fit line may be determined using a variety of functions in addition to or in lieu of a least-squares analysis, and the best fit line may be a linear function, an exponential function, a constant, or any other function type.
  • FIG. 6 illustrates a best fit line for the data range window of 70 mg/dL to 100 mg/dL of reference blood glucose value G b (m) for the sample data set of FIG. 3 .
  • the intercept I(r) values are plotted against the corresponding reference blood glucose values for the centers of the data range windows G bc (r) over all the data range windows.
  • a best fit function or line of a scatter plot of all the intercept values plus the data range center reference blood glucose values I(r)+G bc (r) compared to the data range center reference blood glucose values G bc (r) over all the data range windows is determined ( 280 ).
  • the best fit function may be an affine function or a linear function with an offset, which would suggest a good coherence with a straight line, i.e. a substantially linear response.
  • an R 2 value of 0.9998 is obtained when an affine function is assumed to be the static response of the sensor.
  • the determination of the coefficient of determination, R 2 for a least squares fit of a straight line, is identical to the calculation of the correlation coefficient between the horizontal and vertical axis values of the data points.
  • the calculation of R 2 is standard practice in statistical methods.
  • the weights of the weighted least-squares analysis may include scaling by the number of points in each range, scaling by the inverse of the square of the standard error of the intercept in each range, and scaling by the inverse of the square of the standard deviation of the intercept in each range.
  • the best fit function to data points of intercept values plus the data range center reference blood glucose values I(r)+G bc (r) compared to data range center reference blood glucose values G bc (r) is determined to be not substantially linear, or not an affine function or straight line with an offset, this may be an indication that the response of the sensor being evaluated is not a linear response.
  • a static response corrected slope S c (r) is calculated for each data range window based on the slope S(r) and intercept I(r) for each data range window center reference blood glucose value G bc (r) ( 290 ).
  • a scatter plot of corrected slope S c (r) values over reference blood glucose at the center of data range window G bc (r) values suggests a constant value across the data range windows of the sample data set of FIG. 3 .
  • a weighted average with the number of quadruplets of each data range N(r) as the weight, may be used to estimate an overall time constant of the lag of the sensor.
  • the standard error of the weighted average reflects the consistency of the sensor lag over the reference glucose value G b range.
  • the weights of the weighted average include scaling by the number of points in each range, scaling by the inverse of the square of the standard error of the intercept in each range, and scaling by the inverse of the square of the standard deviation of the intercept in each range.
  • analyte sensor characteristics can be determined for a sensor by utilizing sensor data and the methods described above. Determination of these sensor characteristics may be used, in some embodiments, for, for example, artificial pancreas use, such as the user of an insulin pump or insulin dosing for a patient with Type-1 diabetes utilizing an insulin pump in communication with a continuous glucose monitoring system and associated continuous glucose sensor.
  • method for evaluating characteristics of a continuous analyte sensor includes receiving a plurality of continuous analyte sensor values for corresponding reference analyte values, calculating a rate of change value for the continuous analyte sensor values, defining a plurality of data range windows of the reference analyte values, evaluating the corresponding continuous analyte sensor values, the rate of change values, the reference analyte values, and/or a plurality of corresponding difference values for the plurality of data range windows, and determining a best fit based on the evaluation of the plurality of data range windows.
  • the difference value is the difference between the continuous analyte sensor value and the corresponding reference analyte value.
  • determining the best fit includes determining a least-squares line based on a graphical representation of the rate of change values and the difference values for each of the plurality of data range windows.
  • a further embodiment includes determining a slope and an intercept of the least-squares line for each of the plurality of data range windows.
  • Another further embodiment includes determining a best fit function based on a graphical representation of the intercepts of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a linearity characteristic of the continuous analyte sensor.
  • determining the best fit function includes determining a best fit function based on a weighted graphical representation of the intercepts of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows.
  • the weighted graphical representation includes scaling by the number of points in each data range window, scaling by the inverse of the square of the standard error of the slope in each data range window, or scaling by the inverse of the square of the standard deviation of the slope in each data range window.
  • a further embodiment includes determining a best fit function based on a graphical representation of the slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a lag characteristic of the continuous analyte sensor.
  • determining the best fit function includes determining a best fit function based on a weighted graphical representation of the slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows.
  • the weighted graphical representation includes scaling by the number of points in each data range window, scaling by the inverse of the square of the standard error of the slope in each data range window, or scaling by the inverse of the square of the standard deviation of the slope in each data range window.
  • Another further embodiment includes determining a corrected slope for each of the slopes of the least-squares lines of each of the plurality of data range windows and determining a best fit function based on a graphical representation of the corrected slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a lag characteristic of the continuous analyte sensor.
  • the corrected slope is determined based on weighted slopes of the least-squares lines of each of the plurality of data range windows.
  • an apparatus for evaluating characteristics of a continuous analyte sensor includes one or more processors; and a memory operatively coupled to the one or more processors, the memory storing instructions which, when executed by the one or more processors, causes the one or more processors to receive a plurality of continuous analyte sensor values for corresponding reference analyte values, calculate a rate of change value for the continuous analyte sensor values, define a plurality of data range windows of the reference analyte values, evaluate the corresponding continuous analyte sensor values, the rate of change values, the reference analyte values, and/or a plurality of corresponding difference values for the plurality of data range windows, and determine a best fit based on the evaluation of the plurality of data range windows.

Abstract

Apparatus, method, system and kit for receiving a plurality of continuous analyte sensor values for corresponding reference analyte values, calculating a rate of change value for the continuous analyte sensor values, defining a plurality of data range windows of the reference analyte values, evaluating the corresponding continuous analyte sensor values, the rate of change values, the reference analyte values, and/or a plurality of corresponding difference values for the plurality of data range windows, and determining a best fit based on the evaluation of the plurality of data range windows are provided.

Description

    RELATED APPLICATION
  • The present application claims the benefit of U.S. Provisional Application No. 61/357,986 filed Jun. 23, 2010 entitled “Method and System for Evaluating Analyte Sensor Response Characteristics”, the disclosure of which is incorporated herein by reference for all purposes.
  • BACKGROUND
  • Benefits of a closed loop control system for treating diabetic conditions with monitoring glucose levels and adjusting delivery rate of insulin are well known. Such systems, referred to as artificial pancreas, model healthy pancreas which, when functioning normally, produces insulin (by the beta cells (β-cells)) to counteract the rise in glucose levels in the blood stream. As is known, Type-1 diabetes mellitus condition exists when the beta cells in the pancreas either die or are unable to produce sufficient amount of insulin naturally in response to the elevated glucose levels.
  • Common treatment of Type-1 diabetes is the use of insulin pumps that are programmed to continuous delivery insulin to the body through an infusion set. The use of insulin pumps to treat Type-2 diabetes (where the beta cells in the pancreas do produce insulin, but an inadequate quantity) is also becoming more prevalent. Such insulin delivery devices are preprogrammed with delivery rates such as basal profiles which are tailored to each user, and configured to provide the needed insulin to the user.
  • In addition, continuous glucose monitoring systems have been developed to provide real time monitoring of fluctuation in glucose levels. One example is the FreeStyle Navigator® Continuous Glucose Monitoring System available from Abbott Diabetes Care Inc., of Alameda, Calif. The use of such glucose monitoring systems provides the user with real time glucose level information. Using the continuous glucose monitoring system, for example, diabetics are able to determine when insulin is needed to lower glucose levels or when additional glucose is needed to raise the level of glucose.
  • Using a continuous glucose monitoring system in conjunction with an insulin pump can be an effective treatment tool for individuals with Type-1 or severe Type-2 diabetic condition to maintain their blood sugar levels at a physiologically desirable range. However, for the continuous glucose monitoring system to be effective, characteristics of the continuous glucose monitoring system, particularly the continuous glucose sensor of the system, must be evaluated and accurate. Evaluation of characteristics, such as linearity and lag, associated with continuous glucose sensors can impact glucose control errors and previous methods of evaluating such characteristics, such as linearity, can be confounded by lag, noise and apparent nonlinearities due to data distribution.
  • SUMMARY
  • Accordingly, a method for evaluating characteristics of a continuous analyte sensor in one aspect of the present disclosure includes receiving a plurality of continuous analyte sensor values for corresponding reference analyte values, calculating a rate of change value for the continuous analyte sensor values, defining a plurality of data range windows of the reference analyte values, evaluating the corresponding continuous analyte sensor values, the rate of change values, the reference analyte values, and/or a plurality of corresponding difference values for the plurality of data range windows, and determining a best fit based on the evaluation of the plurality of data range windows is provided.
  • In certain aspects, the difference value is the difference between the continuous analyte sensor value and the corresponding reference analyte value and determining the best fit includes determining a least-squares line or relationship based on a graphical representation of the rate of change of glucose values and the difference values for each of the plurality of data range windows.
  • Certain aspects of the present disclosure include determining a slope and an intercept of the least-squares line for each of the plurality of data range windows and determining a best fit function based on a graphical representation of the intercepts of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, where the best fit function corresponds to a linearity characteristic of the continuous analyte sensor and determining a best fit function based on a graphical representation of the slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, where the best fit function corresponds to a lag characteristic of the continuous analyte sensor are provided.
  • Also provided are systems and kits.
  • INCORPORATED BY REFERENCE
  • The following patents, applications and/or publications are incorporated herein by reference for all purposes: U.S. Pat. Nos. 4,545,382; 4,711,245; 5,262,035; 5,262,305; 5,264,104; 5,320,715; 5,356,786; 5,509,410; 5,543,326; 5,593,852; 5,601,435; 5,628,890; 5,820,551; 5,822,715; 5,899,855; 5,918,603; 6,071,391; 6,103,033; 6,120,676; 6,121,009; 6,134,461; 6,143,164; 6,144,837; 6,161,095; 6,175,752; 6,270,455; 6,284,478; 6,299,757; 6,338,790; 6,377,894; 6,461,496; 6,503,381; 6,514,460; 6,514,718; 6,540,891; 6,560,471; 6,579,690; 6,591,125; 6,592,745; 6,600,997; 6,605,200; 6,605,201; 6,616,819; 6,618,934; 6,650,471; 6,654,625; 6,676,816; 6,730,200; 6,736,957; 6,746,582; 6,749,740; 6,764,581; 6,773,671; 6,881,551; 6,893,545; 6,932,892; 6,932,894; 6,942,518; 7,041,468; 7,167,818; and 7,299,082; U.S. Published Application Nos. 2004/0186365; 2005/0182306; 2006/0025662; 2006/0091006; 2007/0056858; 2007/0068807; 2007/0095661; 2007/0108048; 2007/0199818; 2007/0227911; 2007/0233013; 2008/0066305; 2008/0081977; 2008/0102441; 2008/0148873; 2008/0161666; 2008/0267823; and 2009/0054748; U.S. patent application Ser. Nos. 11/461,725; 12/131,012; 12/242,823; 12/363,712; 12/495,709; 12/698,124; 12/714,439; 12/794,721; 12/848,075; and 12/842,013 and U.S. Provisional Application Ser. No. 61/347,754.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a block diagram illustrating a system for evaluating characteristics of a sensor in one or more embodiments of the present disclosure;
  • FIG. 2 is a flow chart illustrating a method for evaluating characteristics of a sensor response in one or more embodiments of the present disclosure;
  • FIG. 3 is a plot illustrating a sample data set of continuous glucose values and corresponding reference blood glucose values taken at time instances m;
  • FIG. 4 is a plot illustrating the sample data set of FIG. 3 with indication of excluded ranges of reference blood glucose values;
  • FIG. 5 is a plot illustrating a range window of 70 mg/dL to 100 mg/dL of reference glucose values Gb(m) for the sample data set of FIG. 3;
  • FIG. 6 illustrates a best fit line for the range of 70 mg/dL to 100 mg/dL of reference glucose values Gb(m) for the sample data set of FIG. 3;
  • FIG. 7 illustrates a weighted best fit line for the intercepts of the ranges Gbc(r) for the sample data set of FIG. 3; and
  • FIG. 8 illustrates a corrected slope value over the ranges Gbc(r) for the sample data set of FIG. 3.
  • DETAILED DESCRIPTION
  • Before the present disclosure is described in additional detail, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
  • Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
  • It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.
  • The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
  • As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure.
  • The figures shown herein are not necessarily drawn to scale, with some components and features being exaggerated for clarity.
  • As described in further detail below, in accordance with various embodiments of the present disclosure, there is provided methods and systems for evaluating the response of an analyte sensor. In particular, in certain embodiments, there are provided methods for evaluating the linearity and lag characteristics of an analyte sensor. The analyte sensor, in some embodiments, may be part of an analyte monitoring system, such as a glucose monitoring system, such as a continuous glucose monitoring system. Examples of analyte sensors and analyte monitoring systems to which the disclosed methods may be applied can be found in, for example, among others, U.S. Pat. Nos. 6,103,033, 6,134,461, 6,175,752, 6,284,478 and 6,560,471 and in U.S. patent application Ser. Nos. 12/393,921, 12/698,124 and 12/714,439, the disclosures of each of which are incorporated herein by reference in their entirety for all purposes. The analyte sensors and monitoring systems described herein are described mainly with respect to glucose sensors for use with continuous glucose monitoring systems, however, it is to be appreciated that within the scope of the present disclosure, the described methods may be applied to sensors and monitoring systems configured for detection and measurement of other analytes includes, but not limited to, lactate and oxygen, and the sensors may be configured for continuous, substantially continuous, semi-continuous, or periodic measurement.
  • FIG. 1 is a block diagram illustrating a system for evaluating characteristics of an analyte sensor in one or more embodiments of the present disclosure. Referring to FIG. 1, in some embodiments, a system 100 for evaluating characteristics of an analyte sensor includes an analyte monitoring device 110, the analyte monitoring device 110 including an analyte sensor 111 for which characteristics are to be evaluated, and a transmitter module 112 to enable communication with one or more other devices. The system 100 may also include a receiver unit 120 in data communication with the analyte monitoring device 110 and a data processing unit 130, such as a computer or other microprocessor driven device. Other embodiments of the system 100 include a reference blood glucose meter, such as a conventional in vitro blood glucose meter 140. Example analyte monitoring systems can be found in, among others, U.S. Pat. No. 6,175,752, the disclosure of which is incorporated herein by reference for all purposes.
  • Referring still to FIG. 1, the analyte sensor 111 of analyte monitoring device 110, in certain embodiments, is a glucose sensor configured for the continuous monitoring of glucose level fluctuation in a patient or fluid sample. In other embodiments, the sensor may be configured to monitor other analytes, drugs, or chemicals, and may be configured for semi-continuous or periodic measurement. The sensor 111 is in communication with a transmitter module 112 of the analyte monitoring device. The transmitter module 112 is configured to transmit wirelessly or via a wired connection, data signals received from the analyte sensor 111 corresponding to the measured analyte level. In certain embodiments, the analyte monitoring device 110 includes other components (not shown) in addition to the analyte sensor 111 and transmitter module 112, including, but not limited to, one or more processing units, one or more memory units, one or more input and/or output units, a temperature detection module, and a power supply. The components of the analyte monitoring device 110 may be integrated into a single housing or in other embodiments may be in two or more separate housings in data communication with one another.
  • The analyte monitoring device 110, in certain embodiments, is in communication with a receiver unit 120 via the transmitter module 112. The receiver unit 120 is configured to process and/or display data received from the analyte monitoring device. The receiver unit 120, in some embodiments, is in communication with a data processing unit 130, which may be, among others, a personal computer or other microprocessor driven device. The data processing unit 130 may be configured to further process data received from the analyte monitoring device 110 via the receiver unit 120, or directly from the analyte monitoring device via a communication link 150. In certain embodiments, the data processing unit 130 is located at a remote location separated from the analyte monitoring device 110 and receiver unit 120 and data is transferred to the data processing unit 130 via a network, such as a local area network or a wide area network via the internet. The data processing unit 130 may further be in communication with a reference blood glucose meter 140 to receive reference values for use in data processing and evaluation. In other embodiments, reference values may be obtained from other reference devices, which may be specifically chosen based upon the desired analyte, drug, or chemical to be analyzed and evaluated.
  • Each element of the system 100 of FIG. 1 may be individual units, or alternatively, one or more or all of the elements may be integrated into single integrated unit. For example, the reference blood glucose meter 140 may be integrated into the receiver unit 130.
  • Still referring to FIG. 1, each the data processing unit 130 and/or the receiver unit 120 or the analyte monitoring device 110 may be configured to process data received from the sensor 111. Processing data from the sensor 111 may include, among others, evaluating characteristics of the sensor 111, such as calculating lag and/or linearity of the sensor response, as will be described in further detail in conjunction with the flow chart of FIG. 2 below.
  • FIG. 2 is a flow chart illustrating a method for evaluating characteristics of a sensor response in one or more embodiments of the present disclosure. In certain embodiments, a sensor, such as sensor 111 of FIG. 1, is a continuous glucose sensor for which the characteristics, including lag and linearity characteristics are to be evaluated. The evaluation of the sensor characteristics, in some embodiments, is carried out by the data processing unit 130 of the evaluation system 100. In other embodiments, the evaluation is carried out by the receiver unit 120. In still other embodiments, the evaluation is carried out by the analyte monitoring device 110. In accordance with still further embodiments, the evaluation is carried out by a combination of the analyte monitoring device 110, receiver unit 120, and/or the data processing unit 130.
  • Referring back to FIG. 2, the rate of change of a measured analyte (e.g., glucose) level as measured by the continuous glucose sensor, such as analyte sensor 111 of system 100 of FIG. 1, at a given time k, is determined (210). The rate of change at time k, Vi(k), can be calculated, in one embodiment, by choosing or selecting a measurement window with half window Nhr, such that the analyte level values as measured by the continuous glucose sensor Gi(k), in the window are collected {Gi(k−Nhr), . . . Gi(k−1), Gi(k), Gi(k+1), . . . Gi(k+Nhr)}, and an average rate of change of the analyte level is computed or determined from these points.
  • In certain embodiments the half window Nhr is between 1 and 15 minutes with a measurement window of between 3 and 31 minutes, however, it is to be appreciated that the window could be less than 3 minutes or greater than 31 minutes. In some embodiments, the measurement window duration needed for an accurate rate calculation may be based on the sensor type, such that, for example, a continuous, substantially continuous, or semi-continuous sensor which outputs measured analyte levels at a faster rate than an intermittent or periodic sensor, may require a shorter measurement window duration to obtain enough data points for an accurate rate of change calculation, while a periodic sensor may require a longer measurement window duration in order to obtain enough data points for an accurate rate of change calculation. In another embodiment, the rate of change at time k, Vi(k), can be calculated from the slope of a best fit line, such as a least-squares error line, of the points {Gi(k−Nhr), . . . Gi(k−1), Gi(k), Gi(k+1), . . . Gi(k+Nhr)}. In certain embodiments, the rate of change at time k, Vi(k), is calculated by taking two neighboring points Gi(k−Nhr) and Gi(k+Nhr), that are half-window Nhr samples before and after the glucose level value Gi(k), respectively, and then computing the slope between these two neighboring points.
  • Referring still to FIG. 2, after determination of the rate of change calculation of the continuous glucose sensor (210), the rate of change values Vi(m), and the continuous glucose sensor values Gi(m) at time m are matched with reference blood glucose values Gb(m), at time m (220). Matching the rate of change value and continuous glucose sensor value and the reference blood glucose value at time m generates triplets {Gb(m), Gi(m), Vi(m)}. Reference blood glucose values can be obtained in a variety of ways including measuring a blood glucose value in vitro by applying a blood sample to a test strip and measuring the blood glucose value with a conventional blood glucose monitor, such as the reference blood glucose meter 140 of FIG. 1. FIG. 3 is a plot illustrating a sample data set of continuous glucose values and corresponding reference blood glucose values taken at time instances m. For each of these pairs of matched continuous glucose sensor values Gi(m), and reference blood glucose values Gb(m), a corresponding continuous glucose rate of change value Vi(m), also exists.
  • Turning back to FIG. 2, in certain embodiments, once the data set of triplets of {Gb(m), Gi(m), Vi(m)} is determined, the triplets are evaluated to determine which triplets are considered reliable data and which triplets are to be excluded due to unreliability (230). In certain embodiments, the evaluation of the triplets may be based on stratified evaluations of the triplet data taken over predetermined ranges of reference blood glucose values Gb, i.e., wherein each of the predetermined ranges of reference blood glucose values are evaluated individually for the evaluation of the triplets. As such, the evaluations are performed individually on a plurality of groups of reference blood glucose values in order to determine the final result. Furthermore, in certain embodiments, evaluation of each individual range may be utilized for various weighted analysis as described in further detail below. From within each range of reference blood glucose values, the continuous glucose values are evaluated to determine if upper limit or lower limit clipping has occurred. In some embodiments, in evaluated ranges of reference blood glucose values where a significant number of triplets include continuous glucose sensor values Gi that are clipped at the upper or lower range, these ranges of reference blood glucose values Gb are excluded from the data set. Upper and lower clipping limits may be determined based upon the particular sensor being evaluated. For example, the lower clipping limit, in one sensor embodiment, may be 20 mg/dL and the upper clipping limit may be 500 mg/dL. Further, in certain embodiments, if the number of available continuous glucose value data points within a certain reference blood glucose value Gb range is less than a predetermined amount, for example, 100 data points, then these ranges are also excluded from the data set. In another embodiment, the excluded of ranges of reference blood glucose values where a significant number of continuous glucose sensor values Gi are clipped, can be replaced by the statistical method of left and right censoring.
  • As illustrated in FIG. 4, the sample data set of FIG. 3 was evaluated for ranges of reference blood glucose values where substantial clipping occurred and ranges of reference blood glucose values where insufficient continuous glucose data points were present. The result of the evaluation of the sample data set was reference blood glucose values Gb, that fell between 70 mg/dL and 400 mg/dL were evaluated as reliable and the ranges of reference blood glucose values below 70 mg/dL and above 400 mg/dL were excluded from the data set.
  • Returning to FIG. 2, once the data set of triplets of {Gb(m), Gi(m), Vi(m)} is evaluated and ranges of reference blood glucose values Gb are excluded, for example, but not limited to, due to evaluated unreliability as described above, the difference between each continuous glucose sensor value Gi(m) and reference blood glucose value Gb(m) is calculated for all the non-excluded triplets, whereby the difference value ΔG(m) is determined as follows: ΔG(m)=Gi(m)−Gb(m). These difference values ΔG(m) are matched with the corresponding triplets, and quadruplets {Gb(m), Gi(m), Vi(m), ΔG(m)} are generated (240).
  • Still referring to FIG. 2, data range windows of the reference blood glucose values Gb, are defined (250) based on the reference glucose values Gb that were not excluded due to unreliability because of clipping and/or lack of available data points. In certain embodiments, these data range windows of reference blood glucose values Gb are used for stratified analysis of the continuous glucose data when compared with the corresponding reference blood glucose data. The stratified analysis allows for individual analysis and evaluation of the continuous glucose data for each of the corresponding data range windows of reference blood glucose values. As such, the evaluations are performed individually on a plurality of groups of reference blood glucose values in order to determine the final result. Furthermore, in certain embodiments, evaluation of each individual data range window may be utilized for various weighted analysis as described in further detail below. The data range windows may be defined based on the overall data range of values, the number of continuous glucose data values available, or other factors. In one embodiment, the data range windows may be defined as 30 mg/dL data range windows beginning at the lowest non-excluded limit of the reference glucose values Gb.
  • Referring to FIG. 5, if a data range window of 30 mg/dL is defined, the first data range window of the sample data set of FIGS. 3 and 4 may be from 70 mg/dL to 100 mg/dL. Further, the next data range window may be from 100 mg/dL to 130 mg/dL and so on until the ranges reach the upper non-excluded limit of reference glucose value Gb. In certain embodiments, the data range windows may overlap, such that a first data range window is from 70 mg/dL to 100 mg/dL and the next data range window is from 80 mg/dL to 110 mg/dL and so on until the upper non-excluded limit of the reference glucose values Gb is reached. Within each data range window of the reference glucose values Gb, there is a center reference blood glucose value, Gbc(r). For example, the data range window from 70 mg/dL to 100 mg/dL would have a center reference blood glucose value Gbc(r) of 85 mg/dL.
  • For the data set of FIGS. 3 and 4, in one embodiment, the data range window may be defined as 30 mg/dL, and data range center reference blood glucose value Gbc(r) values are at 85, 95, . . . , 375 mg/dL. This also defines the left edges (lower range limit), Gbl(r) to 70, 80, . . . , 360 mg/dL and the right edges (upper range limit), Gbr(r) to 100, 110, . . . , 390 mg/dL. The decision for the distance between the centers of the data range windows, and the amount of overlap (from 0 to almost 100%) may depend on the tradeoff between desired data range resolution (e.g. coarse data range resolution resulting in larger distance between the centers), the allowed maximum correlation between consecutive data ranges (e.g. a smaller allowed maximum correlation results in a smaller allowed percentage of overlap), the available number of data points of the data set used to perform the analysis (e.g. a larger data set allows for shorter distance between the centers of the data range windows and/or smaller amount of overlap), and the type of distribution to be fitted on the data. Appropriate tradeoffs in order to determine the proper distance between the centers of the data range windows and the amount of overlap amongst them would be apparent to those skilled in the art based upon the data set to be evaluated.
  • Referring back to FIG. 2, once the data range windows for the stratified analysis are defined, for each data range value r, where data range value r is the value of the data range window where data is being evaluated or analyzed, the quadruplets of {Gb(m), Gi(m), Vi(m), ΔG(m)} that fall within each data range window are determined (260). Thus, the quadruplets with reference blood glucose value at time m Gb(m) values that are no smaller than the lower range limit, Gbl and no greater than the upper range limit Gbr are collected for the particular data range window. Referring again to FIG. 5, as shown, the quadruplets with reference blood glucose value at time m Gb(m) values between 70 mg/dL and 100 mg/dL are collected in the data range window with reference blood glucose value for the center of the data range Gbc(r)=85 mg/dL.
  • Once the quadruplets of a particular data range window are determined, a best fit line of the difference value ΔG(m) compared to each rate of change value Vi(m) for the data range window is determined (270). In certain embodiments, the best fit line is calculated by setting the rate of change values Vi(m) to be on the x-axis and the corresponding difference value, ΔG(m), to be on the y-axis of a scatter plot for a particular data range window and performing a least-squares error fit of a line between on the points. The least-squares analysis minimizes the sum of the squared residuals of the points and calculates the best fit line of the points. From the least-squares best fit line, the intercept I(r) and slope S(r) of the particular data range window can be calculated. Further, the number of quadruplets that fall within the data range window N(r), can be determined. It will be appreciated by one skilled in the art that the best fit line may be determined using a variety of functions in addition to or in lieu of a least-squares analysis, and the best fit line may be a linear function, an exponential function, a constant, or any other function type. FIG. 6 illustrates a best fit line for the data range window of 70 mg/dL to 100 mg/dL of reference blood glucose value Gb(m) for the sample data set of FIG. 3. As can be seen in the Figure, for the data range center reference blood glucose value Gbc(r)=85 mg/dL (i.e. quadruplets where the reference blood glucose Gb(m) value is between 70 mg/dL and 100 mg/dL), the intercept I(r) and the slope S(r) are, I(r)=3.4 and S(r)=−10, respectively.
  • Referring still to FIG. 2, once the best fit lines of each data range window with center reference blood glucose value Gbc(r) are calculated and each corresponding intercept I(r) and slope S(r) are determined, the intercept I(r) values are plotted against the corresponding reference blood glucose values for the centers of the data range windows Gbc(r) over all the data range windows. A best fit function or line of a scatter plot of all the intercept values plus the data range center reference blood glucose values I(r)+Gbc(r) compared to the data range center reference blood glucose values Gbc(r) over all the data range windows is determined (280). For the sample data set of FIG. 3, the best fit function may be an affine function or a linear function with an offset, which would suggest a good coherence with a straight line, i.e. a substantially linear response.
  • As shown in FIG. 7, when data range window center reference blood glucose values Gbc(r) are taken on the x-axis and corresponding intercept values plus the data range center reference blood glucose values I(r)+Gbc(r) are taken on the y-axis of a graphical representation or plot, if a weighted least-squares best fit straight line is taken between all the points, where the weighting of the least-squares analysis is taken by the number of quadruplets associated with each data range window N(r), the fitness of the line and corresponding affine function of y=0.97x+5.4, validates the linearity of the sensor response of the sensor associated with the data of the sample data set of FIG. 3. For this sample data set, an R2 value of 0.9998 is obtained when an affine function is assumed to be the static response of the sensor. In certain embodiments, the determination of the coefficient of determination, R2, for a least squares fit of a straight line, is identical to the calculation of the correlation coefficient between the horizontal and vertical axis values of the data points. The calculation of R2 is standard practice in statistical methods. In other embodiments, the weights of the weighted least-squares analysis may include scaling by the number of points in each range, scaling by the inverse of the square of the standard error of the intercept in each range, and scaling by the inverse of the square of the standard deviation of the intercept in each range.
  • In certain embodiments, if the best fit function to data points of intercept values plus the data range center reference blood glucose values I(r)+Gbc(r) compared to data range center reference blood glucose values Gbc(r) is determined to be not substantially linear, or not an affine function or straight line with an offset, this may be an indication that the response of the sensor being evaluated is not a linear response.
  • Returning to FIG. 2, a static response corrected slope Sc(r) is calculated for each data range window based on the slope S(r) and intercept I(r) for each data range window center reference blood glucose value Gbc(r) (290). In some embodiments, the corrected slope Sc(r) is calculated as: Sc(r)=S(r)*Gbc(r)/I(r). As illustrated in FIG. 8, a scatter plot of corrected slope Sc(r) values over reference blood glucose at the center of data range window Gbc(r) values suggests a constant value across the data range windows of the sample data set of FIG. 3. A weighted average, with the number of quadruplets of each data range N(r) as the weight, may be used to estimate an overall time constant of the lag of the sensor. In some embodiments, the standard error of the weighted average reflects the consistency of the sensor lag over the reference glucose value Gb range. In certain embodiments, the weights of the weighted average include scaling by the number of points in each range, scaling by the inverse of the square of the standard error of the intercept in each range, and scaling by the inverse of the square of the standard deviation of the intercept in each range.
  • In the manner described above, in certain embodiments, analyte sensor characteristics, including sensor lag and sensor linearity, can be determined for a sensor by utilizing sensor data and the methods described above. Determination of these sensor characteristics may be used, in some embodiments, for, for example, artificial pancreas use, such as the user of an insulin pump or insulin dosing for a patient with Type-1 diabetes utilizing an insulin pump in communication with a continuous glucose monitoring system and associated continuous glucose sensor.
  • In one aspect of the present disclosure, method for evaluating characteristics of a continuous analyte sensor includes receiving a plurality of continuous analyte sensor values for corresponding reference analyte values, calculating a rate of change value for the continuous analyte sensor values, defining a plurality of data range windows of the reference analyte values, evaluating the corresponding continuous analyte sensor values, the rate of change values, the reference analyte values, and/or a plurality of corresponding difference values for the plurality of data range windows, and determining a best fit based on the evaluation of the plurality of data range windows.
  • In one embodiment, the difference value is the difference between the continuous analyte sensor value and the corresponding reference analyte value.
  • In another embodiment, determining the best fit includes determining a least-squares line based on a graphical representation of the rate of change values and the difference values for each of the plurality of data range windows.
  • A further embodiment includes determining a slope and an intercept of the least-squares line for each of the plurality of data range windows.
  • Another further embodiment includes determining a best fit function based on a graphical representation of the intercepts of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a linearity characteristic of the continuous analyte sensor.
  • In one embodiment, determining the best fit function includes determining a best fit function based on a weighted graphical representation of the intercepts of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows.
  • In another embodiment, the weighted graphical representation includes scaling by the number of points in each data range window, scaling by the inverse of the square of the standard error of the slope in each data range window, or scaling by the inverse of the square of the standard deviation of the slope in each data range window.
  • A further embodiment includes determining a best fit function based on a graphical representation of the slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a lag characteristic of the continuous analyte sensor.
  • In one embodiment, determining the best fit function includes determining a best fit function based on a weighted graphical representation of the slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows.
  • In another embodiment, the weighted graphical representation includes scaling by the number of points in each data range window, scaling by the inverse of the square of the standard error of the slope in each data range window, or scaling by the inverse of the square of the standard deviation of the slope in each data range window.
  • Another further embodiment includes determining a corrected slope for each of the slopes of the least-squares lines of each of the plurality of data range windows and determining a best fit function based on a graphical representation of the corrected slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a lag characteristic of the continuous analyte sensor.
  • In one embodiment, the corrected slope is determined based on weighted slopes of the least-squares lines of each of the plurality of data range windows.
  • In another aspect of the present disclosure, an apparatus for evaluating characteristics of a continuous analyte sensor includes one or more processors; and a memory operatively coupled to the one or more processors, the memory storing instructions which, when executed by the one or more processors, causes the one or more processors to receive a plurality of continuous analyte sensor values for corresponding reference analyte values, calculate a rate of change value for the continuous analyte sensor values, define a plurality of data range windows of the reference analyte values, evaluate the corresponding continuous analyte sensor values, the rate of change values, the reference analyte values, and/or a plurality of corresponding difference values for the plurality of data range windows, and determine a best fit based on the evaluation of the plurality of data range windows.
  • Various other modifications and alterations in the structure and method of operation of this disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the embodiments of the present disclosure. Although the present disclosure has been described in connection with particular embodiments, it should be understood that the present disclosure as claimed should not be unduly limited to such particular embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.

Claims (24)

1. A method for evaluating characteristics of a continuous analyte sensor, the method comprising:
receiving a plurality of continuous analyte sensor values for corresponding reference analyte values;
calculating a rate of change value for the continuous analyte sensor values;
defining a plurality of data range windows of the reference analyte values;
evaluating the corresponding continuous analyte sensor values, the rate of change values, the reference analyte values, and/or a plurality of corresponding difference values for the plurality of data range windows; and
determining a best fit based on the evaluation of the plurality of data range windows.
2. The method of claim 1, wherein the difference value is the difference between the continuous analyte sensor value and the corresponding reference analyte value.
3. The method of claim 2, wherein determining the best fit includes determining a least-squares line based on a graphical representation of the rate of change values and the difference values for each of the plurality of data range windows.
4. The method of claim 3, further comprising determining a slope and an intercept of the least-squares line for each of the plurality of data range windows.
5. The method of claim 4, further comprising determining a best fit function based on a graphical representation of the intercepts of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a linearity characteristic of the continuous analyte sensor.
6. The method of claim 5, wherein determining the best fit function includes determining a best fit function based on a weighted graphical representation of the intercepts of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows.
7. The method of claim 6, wherein the weighted graphical representation includes scaling by the number of points in each data range window, scaling by the inverse of the square of the standard error of the slope in each data range window, or scaling by the inverse of the square of the standard deviation of the slope in each data range window.
8. The method of claim 4, further comprising determining a best fit function based on a graphical representation of the slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a lag characteristic of the continuous analyte sensor.
9. The method of claim 8, wherein determining the best fit function includes determining a best fit function based on a weighted graphical representation of the slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows.
10. The method of claim 9, wherein the weighted graphical representation includes scaling by the number of points in each data range window, scaling by the inverse of the square of the standard error of the slope in each data range window, or scaling by the inverse of the square of the standard deviation of the slope in each data range window.
11. The method of claim 4, further comprising determining a corrected slope for each of the slopes of the least-squares lines of each of the plurality of data range windows and determining a best fit function based on a graphical representation of the corrected slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a lag characteristic of the continuous analyte sensor.
12. The method of claim 9, wherein the corrected slope is determined based on weighted slopes of the least-squares lines of each of the plurality of data range windows.
13. An apparatus for evaluating characteristics of a continuous analyte sensor, the apparatus comprising:
one or more processors; and
a memory operatively coupled to the one or more processors, the memory storing instructions which, when executed by the one or more processors, causes the one or more processors to receive a plurality of continuous analyte sensor values for corresponding reference analyte values, calculate a rate of change value for the continuous analyte sensor values, define a plurality of data range windows of the reference analyte values, evaluate the corresponding continuous analyte sensor values, the rate of change values, the reference analyte values, and/or a plurality of corresponding difference values for the plurality of data range windows, and determine a best fit based on the evaluation of the plurality of data range windows.
14. The apparatus of claim 13, wherein the difference value is the difference between the continuous analyte sensor value and the corresponding reference analyte value.
15. The apparatus of claim 14, wherein the instructions to determine the best fit includes instructions to determine a least-squares line based on a graphical representation of the rate of change values and the difference values for the plurality of data range windows.
16. The apparatus of claim 15, wherein the memory further includes instructions which, when executed by the one or more processors, causes the one or more processors to determine a slope and an intercept of the least-squares line for the plurality of data range windows.
17. The apparatus of claim 16, wherein the memory further includes instructions which, when executed by the one or more processors, causes the one or more processors to determine a best fit function based on a graphical representation of the intercepts of the least-squares lines of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a linearity characteristic of the continuous analyte sensor.
18. The apparatus of claim 17, wherein the instructions to determine the best fit function includes instructions to determine a best fit function based on a weighted graphical representation of the intercepts of the least-squares lines of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows.
19. The apparatus of claim 18, wherein the weighted graphical representation includes scaling by the number of points in each data range window, scaling by the inverse of the square of the standard error of the slope in each data range window, or scaling by the inverse of the square of the standard deviation of the slope in each data range window.
20. The apparatus of claim 16, wherein the memory further includes instructions which, when executed by the one or more processors, causes the one or more processors to determine a best fit function based on a graphical representation of the slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a lag characteristic of the continuous analyte sensor.
21. The apparatus of claim 20, wherein the instructions to determine the best fit function includes instructions to determine a best fit function based on a weighted graphical representation of the slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows.
22. The apparatus of claim 21, wherein the weighted graphical representation includes scaling by the number of points in each data range window, scaling by the inverse of the square of the standard error of the slope in each data range window, or scaling by the inverse of the square of the standard deviation of the slope in each data range window.
23. The apparatus of claim 16, wherein the memory further includes instructions which, when executed by the one or more processors, causes the one or more processors to determine a corrected slope for each of the slopes of the least-squares lines of each of the plurality of data range windows and determine a best fit function based on a graphical representation of the corrected slopes of the least-squares lines of each of the plurality of data range windows and the reference analyte values at the centers of the plurality of data range windows, wherein the best fit function corresponds to a lag characteristic of the continuous analyte sensor.
24. The apparatus of claim 23, wherein the corrected slope is determined based on weighted slopes of the least-squares lines of each of the plurality of data range windows.
US13/166,797 2010-06-23 2011-06-22 Method and system for evaluating analyte sensor response characteristics Active 2032-04-13 US8635046B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/166,797 US8635046B2 (en) 2010-06-23 2011-06-22 Method and system for evaluating analyte sensor response characteristics
US14/158,662 US20140136145A1 (en) 2010-06-23 2014-01-17 Method and System for Evaluating Analyte Sensor Response Characteristics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35798610P 2010-06-23 2010-06-23
US13/166,797 US8635046B2 (en) 2010-06-23 2011-06-22 Method and system for evaluating analyte sensor response characteristics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/158,662 Continuation US20140136145A1 (en) 2010-06-23 2014-01-17 Method and System for Evaluating Analyte Sensor Response Characteristics

Publications (2)

Publication Number Publication Date
US20110320167A1 true US20110320167A1 (en) 2011-12-29
US8635046B2 US8635046B2 (en) 2014-01-21

Family

ID=45353346

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/166,797 Active 2032-04-13 US8635046B2 (en) 2010-06-23 2011-06-22 Method and system for evaluating analyte sensor response characteristics
US14/158,662 Abandoned US20140136145A1 (en) 2010-06-23 2014-01-17 Method and System for Evaluating Analyte Sensor Response Characteristics

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/158,662 Abandoned US20140136145A1 (en) 2010-06-23 2014-01-17 Method and System for Evaluating Analyte Sensor Response Characteristics

Country Status (1)

Country Link
US (2) US8635046B2 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8571808B2 (en) 2007-05-14 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8583205B2 (en) 2008-03-28 2013-11-12 Abbott Diabetes Care Inc. Analyte sensor calibration management
WO2014052136A1 (en) 2012-09-26 2014-04-03 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US8718958B2 (en) 2006-10-26 2014-05-06 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US9549694B2 (en) 2009-08-31 2017-01-24 Abbott Diabetes Care Inc. Displays for a medical device
US9622691B2 (en) 2011-10-31 2017-04-18 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US9795326B2 (en) 2009-07-23 2017-10-24 Abbott Diabetes Care Inc. Continuous analyte measurement systems and systems and methods for implanting them
US9936910B2 (en) 2009-07-31 2018-04-10 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring and therapy management system accuracy
US10076285B2 (en) 2013-03-15 2018-09-18 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10346228B2 (en) * 2017-07-12 2019-07-09 Siemens Aktiengesellschaft Method and system for deviation detection in sensor datasets
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US10555695B2 (en) 2011-04-15 2020-02-11 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US11213226B2 (en) 2010-10-07 2022-01-04 Abbott Diabetes Care Inc. Analyte monitoring devices and methods
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11553883B2 (en) 2015-07-10 2023-01-17 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
US11717225B2 (en) 2014-03-30 2023-08-08 Abbott Diabetes Care Inc. Method and apparatus for determining meal start and peak events in analyte monitoring systems

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD779504S1 (en) 2014-11-14 2017-02-21 Dexcom, Inc. Display screen or portion thereof with graphical user interface for presentation of analyte data
USD779505S1 (en) 2014-11-14 2017-02-21 Dexcom, Inc. Display screen or portion thereof with graphical user interface for analyte data presentation
CA3012444C (en) 2016-02-05 2022-06-14 Animas Corporation Visualization and analysis tool for a drug delivery system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7016713B2 (en) * 1995-08-09 2006-03-21 Inlight Solutions, Inc. Non-invasive determination of direction and rate of change of an analyte

Family Cites Families (666)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1191363A (en) 1968-02-19 1970-05-13 Pavelle Ltd Improvements in or relating to Electronic Thermostats.
US3949388A (en) 1972-11-13 1976-04-06 Monitron Industries, Inc. Physiological sensor and transmitter
US3926760A (en) 1973-09-28 1975-12-16 Du Pont Process for electrophoretic deposition of polymer
US4245634A (en) 1975-01-22 1981-01-20 Hospital For Sick Children Artificial beta cell
US3978856A (en) 1975-03-20 1976-09-07 Michel Walter A Heart beat waveform monitoring apparatus
US4036749A (en) 1975-04-30 1977-07-19 Anderson Donald R Purification of saline water
US4055175A (en) 1976-05-07 1977-10-25 Miles Laboratories, Inc. Blood glucose control apparatus
US4129128A (en) 1977-02-23 1978-12-12 Mcfarlane Richard H Securing device for catheter placement assembly
US4344438A (en) 1978-08-02 1982-08-17 The United States Of America As Represented By The Department Of Health, Education And Welfare Optical sensor of plasma constituents
AU530979B2 (en) 1978-12-07 1983-08-04 Aus. Training Aids Pty. Ltd., Detecting position of bullet fired at target
US4373527B1 (en) 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
US4731051A (en) 1979-04-27 1988-03-15 The Johns Hopkins University Programmable control means for providing safe and controlled medication infusion
CS210174B1 (en) 1979-07-12 1982-01-29 Ivan Emmer Method of making the electric hygrometric sensor
US4425920A (en) 1980-10-24 1984-01-17 Purdue Research Foundation Apparatus and method for measurement and control of blood pressure
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4392849A (en) 1981-07-27 1983-07-12 The Cleveland Clinic Foundation Infusion pump controller
DE3138194A1 (en) 1981-09-25 1983-04-14 Basf Ag, 6700 Ludwigshafen WATER-INSOLUBLE POROESES PROTEIN MATERIAL, THEIR PRODUCTION AND USE
US4494950A (en) 1982-01-19 1985-01-22 The Johns Hopkins University Plural module medication delivery system
US4462048A (en) 1982-02-11 1984-07-24 Rca Corporation Noise reduction circuitry for audio signals
FI831399L (en) 1982-04-29 1983-10-30 Agripat Sa KONTAKTLINS AV HAERDAD POLYVINYL ALCOHOL
EP0098592A3 (en) 1982-07-06 1985-08-21 Fujisawa Pharmaceutical Co., Ltd. Portable artificial pancreas
US4509531A (en) 1982-07-28 1985-04-09 Teledyne Industries, Inc. Personal physiological monitor
US4527240A (en) 1982-12-29 1985-07-02 Kvitash Vadim I Balascopy method for detecting and rapidly evaluating multiple imbalances within multi-parametric systems
CA1226036A (en) 1983-05-05 1987-08-25 Irving J. Higgins Analytical equipment and sensor electrodes therefor
US5509410A (en) 1983-06-06 1996-04-23 Medisense, Inc. Strip electrode including screen printing of a single layer
US4538616A (en) 1983-07-25 1985-09-03 Robert Rogoff Blood sugar level sensing and monitoring transducer
DE3429596A1 (en) 1984-08-10 1986-02-20 Siemens AG, 1000 Berlin und 8000 München DEVICE FOR THE PHYSIOLOGICAL FREQUENCY CONTROL OF A PACEMAKER PROVIDED WITH A PICTURE ELECTRODE
CA1254091A (en) 1984-09-28 1989-05-16 Vladimir Feingold Implantable medication infusion system
US5279294A (en) 1985-04-08 1994-01-18 Cascade Medical, Inc. Medical diagnostic system
US4671288A (en) 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
US4890620A (en) 1985-09-20 1990-01-02 The Regents Of The University Of California Two-dimensional diffusion glucose substrate sensing electrode
US4759366A (en) 1986-03-19 1988-07-26 Telectronics N.V. Rate responsive pacing using the ventricular gradient
US4757022A (en) 1986-04-15 1988-07-12 Markwell Medical Institute, Inc. Biological fluid measuring device
US4703756A (en) 1986-05-06 1987-11-03 The Regents Of The University Of California Complete glucose monitoring system with an implantable, telemetered sensor module
US4731726A (en) 1986-05-19 1988-03-15 Healthware Corporation Patient-operated glucose monitor and diabetes management system
US5055171A (en) 1986-10-06 1991-10-08 T And G Corporation Ionic semiconductor materials and applications thereof
US4777953A (en) 1987-02-25 1988-10-18 Ash Medical Systems, Inc. Capillary filtration and collection method for long-term monitoring of blood constituents
US5002054A (en) 1987-02-25 1991-03-26 Ash Medical Systems, Inc. Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body
US4854322A (en) 1987-02-25 1989-08-08 Ash Medical Systems, Inc. Capillary filtration and collection device for long-term monitoring of blood constituents
US5365426A (en) 1987-03-13 1994-11-15 The University Of Maryland Advanced signal processing methodology for the detection, localization and quantification of acute myocardial ischemia
US4759828A (en) 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US4749985A (en) 1987-04-13 1988-06-07 United States Of America As Represented By The United States Department Of Energy Functional relationship-based alarm processing
EP0290683A3 (en) 1987-05-01 1988-12-14 Diva Medical Systems B.V. Diabetes management system and apparatus
GB8725936D0 (en) 1987-11-05 1987-12-09 Genetics Int Inc Sensing system
US4925268A (en) 1988-07-25 1990-05-15 Abbott Laboratories Fiber-optic physiological probes
EP0353328A1 (en) 1988-08-03 1990-02-07 Dräger Nederland B.V. A polarographic-amperometric three-electrode sensor
US5340722A (en) 1988-08-24 1994-08-23 Avl Medical Instruments Ag Method for the determination of the concentration of an enzyme substrate and a sensor for carrying out the method
US5108889A (en) 1988-10-12 1992-04-28 Thorne, Smith, Astill Technologies, Inc. Assay for determining analyte using mercury release followed by detection via interaction with aluminum
US5360404A (en) 1988-12-14 1994-11-01 Inviro Medical Devices Ltd. Needle guard and needle assembly for syringe
US4947845A (en) 1989-01-13 1990-08-14 Pacesetter Infusion, Ltd. Method of maximizing catheter longevity in an implantable medication infusion system
US5068536A (en) 1989-01-19 1991-11-26 Futrex, Inc. Method for providing custom calibration for near infrared instruments for measurement of blood glucose
US5077476A (en) 1990-06-27 1991-12-31 Futrex, Inc. Instrument for non-invasive measurement of blood glucose
DE69027233T2 (en) 1989-03-03 1996-10-10 Edward W Stark Signal processing method and apparatus
JPH02298855A (en) 1989-03-20 1990-12-11 Assoc Univ Inc Electrochemical biosensor using immobilized enzyme and redox polymer
US4953552A (en) 1989-04-21 1990-09-04 Demarzo Arthur P Blood glucose monitoring system
EP0396788A1 (en) 1989-05-08 1990-11-14 Dräger Nederland B.V. Process and sensor for measuring the glucose content of glucosecontaining fluids
FR2648353B1 (en) 1989-06-16 1992-03-27 Europhor Sa MICRODIALYSIS PROBE
US5431160A (en) 1989-07-19 1995-07-11 University Of New Mexico Miniature implantable refillable glucose sensor and material therefor
US4986271A (en) 1989-07-19 1991-01-22 The University Of New Mexico Vivo refillable glucose sensor
US5262035A (en) 1989-08-02 1993-11-16 E. Heller And Company Enzyme electrodes
US5264105A (en) 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US5320725A (en) 1989-08-02 1994-06-14 E. Heller & Company Electrode and method for the detection of hydrogen peroxide
US5264104A (en) 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US5568400A (en) 1989-09-01 1996-10-22 Stark; Edward W. Multiplicative signal correction method and apparatus
US5050612A (en) 1989-09-12 1991-09-24 Matsumura Kenneth N Device for computer-assisted monitoring of the body
US5082550A (en) 1989-12-11 1992-01-21 The United States Of America As Represented By The Department Of Energy Enzyme electrochemical sensor electrode and method of making it
US5342789A (en) 1989-12-14 1994-08-30 Sensor Technologies, Inc. Method and device for detecting and quantifying glucose in body fluids
US5165407A (en) 1990-04-19 1992-11-24 The University Of Kansas Implantable glucose sensor
GB2243211A (en) 1990-04-20 1991-10-23 Philips Electronic Associated Analytical instrument and method of calibrating an analytical instrument
US5202261A (en) 1990-07-19 1993-04-13 Miles Inc. Conductive sensors and their use in diagnostic assays
US5113869A (en) 1990-08-21 1992-05-19 Telectronics Pacing Systems, Inc. Implantable ambulatory electrocardiogram monitor
EP0550641B1 (en) 1990-09-28 1994-05-25 Pfizer Inc. Dispensing device containing a hydrophobic medium
DE69126885T3 (en) 1990-12-12 2001-10-18 Sherwood Serv Ag CALIBRATION OF AN INFRARED THERMOMETER BY MEANS OF AREA CALIBRATION DISPLAY
US5148812A (en) 1991-02-20 1992-09-22 Georgetown University Non-invasive dynamic tracking of cardiac vulnerability by analysis of t-wave alternans
JPH04278450A (en) 1991-03-04 1992-10-05 Adam Heller Biosensor and method for analyzing subject
US5593852A (en) 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US5262305A (en) 1991-03-04 1993-11-16 E. Heller & Company Interferant eliminating biosensors
US5469855A (en) 1991-03-08 1995-11-28 Exergen Corporation Continuous temperature monitor
US5135004A (en) 1991-03-12 1992-08-04 Incontrol, Inc. Implantable myocardial ischemia monitor and related method
US5199428A (en) 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5122925A (en) 1991-04-22 1992-06-16 Control Products, Inc. Package for electronic components
US5868711A (en) 1991-04-29 1999-02-09 Board Of Regents, The University Of Texas System Implantable intraosseous device for rapid vascular access
US5328460A (en) 1991-06-21 1994-07-12 Pacesetter Infusion, Ltd. Implantable medication infusion pump including self-contained acoustic fault detection apparatus
CA2074702C (en) 1991-07-29 1996-11-19 Donald J. Urbas Programmable transponder
US5231988A (en) 1991-08-09 1993-08-03 Cyberonics, Inc. Treatment of endocrine disorders by nerve stimulation
GB9120144D0 (en) 1991-09-20 1991-11-06 Imperial College A dialysis electrode device
US5322063A (en) 1991-10-04 1994-06-21 Eli Lilly And Company Hydrophilic polyurethane membranes for electrochemical glucose sensors
US5203326A (en) 1991-12-18 1993-04-20 Telectronics Pacing Systems, Inc. Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
US5372427A (en) 1991-12-19 1994-12-13 Texas Instruments Incorporated Temperature sensor
US5285792A (en) 1992-01-10 1994-02-15 Physio-Control Corporation System for producing prioritized alarm messages in a medical instrument
US5313953A (en) 1992-01-14 1994-05-24 Incontrol, Inc. Implantable cardiac patient monitor
US5246867A (en) 1992-01-17 1993-09-21 University Of Maryland At Baltimore Determination and quantification of saccharides by luminescence lifetimes and energy transfer
IL104365A0 (en) 1992-01-31 1993-05-13 Gensia Pharma Method and apparatus for closed loop drug delivery
US5328927A (en) 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
DE69319771T2 (en) 1992-03-31 1999-04-22 Dainippon Printing Co Ltd Immobilized enzyme electrode, composition for its production and electrically conductive enzymes
ATE197761T1 (en) 1992-04-03 2000-12-15 Micromedical Ind Ltd ARRANGEMENT FOR MONITORING PHYSIOLOGICAL PARAMETERS
US5711001A (en) 1992-05-08 1998-01-20 Motorola, Inc. Method and circuit for acquisition by a radio receiver
GB9211402D0 (en) 1992-05-29 1992-07-15 Univ Manchester Sensor devices
DK95792A (en) 1992-07-24 1994-01-25 Radiometer As Sensor for non-invasive, in vivo determination of an analyte and blood flow
US5330634A (en) 1992-08-28 1994-07-19 Via Medical Corporation Calibration solutions useful for analyses of biological fluids and methods employing same
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US5376070A (en) 1992-09-29 1994-12-27 Minimed Inc. Data transfer system for an infusion pump
WO1994010553A1 (en) 1992-10-23 1994-05-11 Optex Biomedical, Inc. Fibre-optic probe for the measurement of fluid parameters
US5956501A (en) 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
US5601435A (en) 1994-11-04 1997-02-11 Intercare Method and apparatus for interactively monitoring a physiological condition and for interactively providing health related information
US5899855A (en) 1992-11-17 1999-05-04 Health Hero Network, Inc. Modular microprocessor-based health monitoring system
ZA938555B (en) 1992-11-23 1994-08-02 Lilly Co Eli Technique to improve the performance of electrochemical sensors
US5299571A (en) 1993-01-22 1994-04-05 Eli Lilly And Company Apparatus and method for implantation of sensors
DE59410066D1 (en) 1993-04-23 2002-04-11 Boehringer Mannheim Gmbh System for analyzing the contents of liquid samples
US5384547A (en) 1993-08-02 1995-01-24 Motorola, Inc. Apparatus and method for attenuating a multicarrier input signal of a linear device
DE4329898A1 (en) 1993-09-04 1995-04-06 Marcus Dr Besson Wireless medical diagnostic and monitoring device
US5425749A (en) 1993-09-16 1995-06-20 Angeion Corporation Preemptive cardioversion therapy in an implantable cardioverter defibrillator
US5582184A (en) 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5400795A (en) 1993-10-22 1995-03-28 Telectronics Pacing Systems, Inc. Method of classifying heart rhythms by analyzing several morphology defining metrics derived for a patient's QRS complex
US5791344A (en) 1993-11-19 1998-08-11 Alfred E. Mann Foundation For Scientific Research Patient monitoring system
US5497772A (en) 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
DE4401400A1 (en) 1994-01-19 1995-07-20 Ernst Prof Dr Pfeiffer Method and arrangement for continuously monitoring the concentration of a metabolite
US5536249A (en) 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5390671A (en) 1994-03-15 1995-02-21 Minimed Inc. Transcutaneous sensor insertion set
US5391250A (en) 1994-03-15 1995-02-21 Minimed Inc. Method of fabricating thin film sensors
US5609575A (en) 1994-04-11 1997-03-11 Graseby Medical Limited Infusion pump and method with dose-rate calculation
US5569186A (en) 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
DE4415896A1 (en) 1994-05-05 1995-11-09 Boehringer Mannheim Gmbh Analysis system for monitoring the concentration of an analyte in the blood of a patient
US5472317A (en) 1994-06-03 1995-12-05 Minimed Inc. Mounting clip for a medication infusion pump
US5549115A (en) 1994-09-28 1996-08-27 Heartstream, Inc. Method and apparatus for gathering event data using a removable data storage medium and clock
US6038469A (en) 1994-10-07 2000-03-14 Ortivus Ab Myocardial ischemia and infarction analysis and monitoring method and apparatus
US5520191A (en) 1994-10-07 1996-05-28 Ortivus Medical Ab Myocardial ischemia and infarction analysis and monitoring method and apparatus
US5724030A (en) 1994-10-13 1998-03-03 Bio Medic Data Systems, Inc. System monitoring reprogrammable implantable transponder
US5586553A (en) 1995-02-16 1996-12-24 Minimed Inc. Transcutaneous sensor insertion set
US5568806A (en) 1995-02-16 1996-10-29 Minimed Inc. Transcutaneous sensor insertion set
US5628310A (en) 1995-05-19 1997-05-13 Joseph R. Lakowicz Method and apparatus to perform trans-cutaneous analyte monitoring
US5995860A (en) 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US5665222A (en) 1995-10-11 1997-09-09 E. Heller & Company Soybean peroxidase electrochemical sensor
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
US5711861A (en) 1995-11-22 1998-01-27 Ward; W. Kenneth Device for monitoring changes in analyte concentration
FI960636A (en) 1996-02-12 1997-08-13 Nokia Mobile Phones Ltd A procedure for monitoring the health of a patient
US5785660A (en) 1996-03-28 1998-07-28 Pacesetter, Inc. Methods and apparatus for storing intracardiac electrograms
DE19618597B4 (en) 1996-05-09 2005-07-21 Institut für Diabetestechnologie Gemeinnützige Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm Method for determining the concentration of tissue glucose
US6130602A (en) 1996-05-13 2000-10-10 Micron Technology, Inc. Radio frequency data communications device
US20040249420A1 (en) 1996-05-14 2004-12-09 Medtronic, Inc. Prioritized rule based method and apparatus for diagnosis and treatment of arrhythmias
US5735285A (en) 1996-06-04 1998-04-07 Data Critical Corp. Method and hand-held apparatus for demodulating and viewing frequency modulated biomedical signals
US6230051B1 (en) 1996-06-18 2001-05-08 Alza Corporation Device for enhancing transdermal agent delivery or sampling
AU3596597A (en) 1996-07-08 1998-02-02 Animas Corporation Implantable sensor and system for in vivo measurement and control of fluid constituent levels
US5707502A (en) 1996-07-12 1998-01-13 Chiron Diagnostics Corporation Sensors for measuring analyte concentrations and methods of making same
US6544193B2 (en) 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
US5720295A (en) 1996-10-15 1998-02-24 Pacesetter, Inc. Pacemaker with improved detection of atrial fibrillation
US6071249A (en) 1996-12-06 2000-06-06 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
US5964993A (en) 1996-12-19 1999-10-12 Implanted Biosystems Inc. Glucose sensor
US6130623A (en) 1996-12-31 2000-10-10 Lucent Technologies Inc. Encryption for modulated backscatter systems
US5914026A (en) 1997-01-06 1999-06-22 Implanted Biosystems Inc. Implantable sensor employing an auxiliary electrode
US6122351A (en) 1997-01-21 2000-09-19 Med Graph, Inc. Method and system aiding medical diagnosis and treatment
SE9700182D0 (en) 1997-01-22 1997-01-22 Pacesetter Ab Implantable heart stimulator
SE9700181D0 (en) 1997-01-22 1997-01-22 Pacesetter Ab Ischemia detector and heart stimulator provided with such an ischemia detector
US6607509B2 (en) 1997-12-31 2003-08-19 Medtronic Minimed, Inc. Insertion device for an insertion set and method of using the same
US6093172A (en) 1997-02-05 2000-07-25 Minimed Inc. Injector for a subcutaneous insertion set
EP0958495B1 (en) 1997-02-06 2002-11-13 Therasense, Inc. Small volume in vitro analyte sensor
SE9700427D0 (en) 1997-02-07 1997-02-07 Pacesetter Ab Ischemia detector
US5749907A (en) 1997-02-18 1998-05-12 Pacesetter, Inc. System and method for identifying and displaying medical data which violate programmable alarm conditions
EP1011426A1 (en) 1997-02-26 2000-06-28 Diasense, Inc. Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose
US6159147A (en) 1997-02-28 2000-12-12 Qrs Diagnostics, Llc Personal computer card for collection of real-time biological data
US7899511B2 (en) 2004-07-13 2011-03-01 Dexcom, Inc. Low oxygen in vivo analyte sensor
US7657297B2 (en) 2004-05-03 2010-02-02 Dexcom, Inc. Implantable analyte sensor
US6558321B1 (en) 1997-03-04 2003-05-06 Dexcom, Inc. Systems and methods for remote monitoring and modulation of medical devices
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US6741877B1 (en) 1997-03-04 2004-05-25 Dexcom, Inc. Device and method for determining analyte levels
US20050033132A1 (en) 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
US6862465B2 (en) 1997-03-04 2005-03-01 Dexcom, Inc. Device and method for determining analyte levels
US5959529A (en) 1997-03-07 1999-09-28 Kail, Iv; Karl A. Reprogrammable remote sensor monitoring system
US5891047A (en) 1997-03-14 1999-04-06 Cambridge Heart, Inc. Detecting abnormal activation of heart
US5792065A (en) 1997-03-18 1998-08-11 Marquette Medical Systems, Inc. Method and apparatus for determining T-wave marker points during QT dispersion analysis
SE9701121D0 (en) 1997-03-26 1997-03-26 Pacesetter Ab Implantable heart stimulator
SE9701122D0 (en) 1997-03-26 1997-03-26 Pacesetter Ab Medical implant
US5961451A (en) 1997-04-07 1999-10-05 Motorola, Inc. Noninvasive apparatus having a retaining member to retain a removable biosensor
US5942979A (en) 1997-04-07 1999-08-24 Luppino; Richard On guard vehicle safety warning system
US5935224A (en) 1997-04-24 1999-08-10 Microsoft Corporation Method and apparatus for adaptively coupling an external peripheral device to either a universal serial bus port on a computer or hub or a game port on a computer
US7267665B2 (en) 1999-06-03 2007-09-11 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US5954643A (en) 1997-06-09 1999-09-21 Minimid Inc. Insertion set for a transcutaneous sensor
US6558351B1 (en) 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
CA2294610A1 (en) 1997-06-16 1998-12-23 George Moshe Katz Methods of calibrating and testing a sensor for in vivo measurement of an analyte and devices for use in such methods
US6731976B2 (en) 1997-09-03 2004-05-04 Medtronic, Inc. Device and method to measure and communicate body parameters
US6117290A (en) 1997-09-26 2000-09-12 Pepex Biomedical, Llc System and method for measuring a bioanalyte such as lactate
US5904671A (en) 1997-10-03 1999-05-18 Navot; Nir Tampon wetness detection system
US6088608A (en) 1997-10-20 2000-07-11 Alfred E. Mann Foundation Electrochemical sensor and integrity tests therefor
US6119028A (en) 1997-10-20 2000-09-12 Alfred E. Mann Foundation Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces
FI107080B (en) 1997-10-27 2001-05-31 Nokia Mobile Phones Ltd measuring device
CA2305366C (en) 1997-11-12 2007-10-16 Lightouch Medical, Inc. Method for non-invasive measurement of an analyte
NZ504879A (en) 1997-12-04 2003-05-30 Roche Diagnostics Corp Instrument for engaging a power cell
US6579690B1 (en) 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
US6073031A (en) 1997-12-24 2000-06-06 Nortel Networks Corporation Desktop docking station for use with a wireless telephone handset
CA2312919C (en) 1997-12-31 2004-12-14 Minimed, Inc. Insertion device for an insertion set and method of using the same
US6103033A (en) 1998-03-04 2000-08-15 Therasense, Inc. Process for producing an electrochemical biosensor
US6134461A (en) 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6024699A (en) 1998-03-13 2000-02-15 Healthware Corporation Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients
US6579231B1 (en) 1998-03-27 2003-06-17 Mci Communications Corporation Personal medical monitoring unit and system
JP3104672B2 (en) 1998-03-31 2000-10-30 日本電気株式会社 Current detection type sensor element and method of manufacturing the same
JPH11296598A (en) 1998-04-07 1999-10-29 Seizaburo Arita System and method for predicting blood-sugar level and record medium where same method is recorded
US6091987A (en) 1998-04-29 2000-07-18 Medtronic, Inc. Power consumption reduction in medical devices by employing different supply voltages
US7647237B2 (en) 1998-04-29 2010-01-12 Minimed, Inc. Communication station and software for interfacing with an infusion pump, analyte monitor, analyte meter, or the like
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
CA2311487C (en) 1998-05-13 2004-02-10 Cygnus, Inc. Signal processing for measurement of physiological analytes
CA2332112C (en) 1998-05-13 2004-02-10 Cygnus, Inc. Monitoring of physiological analytes
US7043287B1 (en) 1998-05-18 2006-05-09 Abbott Laboratories Method for modulating light penetration depth in tissue and diagnostic applications using same
US6121611A (en) 1998-05-20 2000-09-19 Molecular Imaging Corporation Force sensing probe for scanning probe microscopy
AU5394099A (en) 1998-08-07 2000-02-28 Infinite Biomedical Technologies, Incorporated Implantable myocardial ischemia detection, indication and action technology
US6558320B1 (en) 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
US6248067B1 (en) 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same
US6740518B1 (en) 1998-09-17 2004-05-25 Clinical Micro Sensors, Inc. Signal detection techniques for the detection of analytes
US6254586B1 (en) 1998-09-25 2001-07-03 Minimed Inc. Method and kit for supplying a fluid to a subcutaneous placement site
DK1102559T3 (en) 1998-09-30 2003-09-29 Cygnus Therapeutic Systems Method and apparatus for predicting physiological values
US6338790B1 (en) 1998-10-08 2002-01-15 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
AU6255699A (en) 1998-10-08 2000-04-26 Minimed, Inc. Telemetered characteristic monitor system
US6591125B1 (en) 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6496729B2 (en) 1998-10-28 2002-12-17 Medtronic, Inc. Power consumption reduction in medical devices employing multiple supply voltages and clock frequency control
US6602469B1 (en) 1998-11-09 2003-08-05 Lifestream Technologies, Inc. Health monitoring and diagnostic device and network-based health assessment and medical records maintenance system
EP1130996B1 (en) 1998-11-20 2005-04-13 The University of Connecticut Generic integrated implantable potentiostat telemetry unit for electrochemical sensors
KR100627990B1 (en) 1998-11-30 2006-09-26 노보 노르디스크 에이/에스 A method and a system for assisting a user in a medical self treatment, said self treatment comprising a plurality of actions
US7436511B2 (en) 1999-01-22 2008-10-14 Sensys Medical, Inc. Analyte filter method and apparatus
CA2365609A1 (en) 1999-02-12 2000-08-17 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
US6112116A (en) 1999-02-22 2000-08-29 Cathco, Inc. Implantable responsive system for sensing and treating acute myocardial infarction
US6424847B1 (en) 1999-02-25 2002-07-23 Medtronic Minimed, Inc. Glucose monitor calibration methods
US6360888B1 (en) 1999-02-25 2002-03-26 Minimed Inc. Glucose sensor package system
US8103325B2 (en) 1999-03-08 2012-01-24 Tyco Healthcare Group Lp Method and circuit for storing and providing historical physiological data
US6272379B1 (en) 1999-03-17 2001-08-07 Cathco, Inc. Implantable electronic system with acute myocardial infarction detection and patient warning capabilities
US6115628A (en) 1999-03-29 2000-09-05 Medtronic, Inc. Method and apparatus for filtering electrocardiogram (ECG) signals to remove bad cycle information and for use of physiologic signals determined from said filtered ECG signals
US6128526A (en) 1999-03-29 2000-10-03 Medtronic, Inc. Method for ischemia detection and apparatus for using same
US6285897B1 (en) 1999-04-07 2001-09-04 Endonetics, Inc. Remote physiological monitoring system
US6416471B1 (en) 1999-04-15 2002-07-09 Nexan Limited Portable remote patient telemonitoring system
US6200265B1 (en) 1999-04-16 2001-03-13 Medtronic, Inc. Peripheral memory patch and access method for use with an implantable medical device
US6108577A (en) 1999-04-26 2000-08-22 Cardiac Pacemakers, Inc. Method and apparatus for detecting changes in electrocardiogram signals
US6669663B1 (en) 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
US6359444B1 (en) 1999-05-28 2002-03-19 University Of Kentucky Research Foundation Remote resonant-circuit analyte sensing apparatus with sensing structure and associated method of sensing
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
US6423035B1 (en) 1999-06-18 2002-07-23 Animas Corporation Infusion pump with a sealed drive mechanism and improved method of occlusion detection
WO2000078992A2 (en) 1999-06-18 2000-12-28 Therasense, Inc. Mass transport limited in vivo analyte sensor
US7522878B2 (en) 1999-06-21 2009-04-21 Access Business Group International Llc Adaptive inductive power supply with communication
US6413393B1 (en) 1999-07-07 2002-07-02 Minimed, Inc. Sensor including UV-absorbing polymer and method of manufacture
US6804558B2 (en) 1999-07-07 2004-10-12 Medtronic, Inc. System and method of communicating between an implantable medical device and a remote computer system or health care provider
US6471689B1 (en) 1999-08-16 2002-10-29 Thomas Jefferson University Implantable drug delivery catheter system with capillary interface
US6923763B1 (en) 1999-08-23 2005-08-02 University Of Virginia Patent Foundation Method and apparatus for predicting the risk of hypoglycemia
US7113821B1 (en) 1999-08-25 2006-09-26 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery
US6343225B1 (en) 1999-09-14 2002-01-29 Implanted Biosystems, Inc. Implantable glucose sensor
AT408182B (en) 1999-09-17 2001-09-25 Schaupp Lukas Dipl Ing Dr Tech DEVICE FOR VIVO MEASURING SIZES IN LIVING ORGANISMS
EP1217942A1 (en) 1999-09-24 2002-07-03 Healthetech, Inc. Physiological monitor and associated computation, display and communication unit
US6294997B1 (en) 1999-10-04 2001-09-25 Intermec Ip Corp. RFID tag having timing and environment modules
US7317938B2 (en) 1999-10-08 2008-01-08 Sensys Medical, Inc. Method of adapting in-vitro models to aid in noninvasive glucose determination
US6478736B1 (en) 1999-10-08 2002-11-12 Healthetech, Inc. Integrated calorie management system
US6249705B1 (en) 1999-10-21 2001-06-19 Pacesetter, Inc. Distributed network system for use with implantable medical devices
US6616819B1 (en) 1999-11-04 2003-09-09 Therasense, Inc. Small volume in vitro analyte sensor and methods
DK1230249T3 (en) 1999-11-15 2004-08-30 Therasense Inc Transition metal complexes with bidentate ligand having an imidazole ring
US6291200B1 (en) 1999-11-17 2001-09-18 Agentase, Llc Enzyme-containing polymeric sensors
US6658396B1 (en) 1999-11-29 2003-12-02 Tang Sharon S Neural network drug dosage estimation
US6418346B1 (en) 1999-12-14 2002-07-09 Medtronic, Inc. Apparatus and method for remote therapy and diagnosis in medical devices via interface systems
US6497655B1 (en) 1999-12-17 2002-12-24 Medtronic, Inc. Virtual remote monitor, alert, diagnostics and programming for implantable medical device systems
US7060031B2 (en) 1999-12-17 2006-06-13 Medtronic, Inc. Method and apparatus for remotely programming implantable medical devices
US6377852B1 (en) 2000-01-20 2002-04-23 Pacesetter, Inc. Implanatable cardiac stimulation device and method for prolonging atrial refractoriness
US7369635B2 (en) 2000-01-21 2008-05-06 Medtronic Minimed, Inc. Rapid discrimination preambles and methods for using the same
US6733446B2 (en) 2000-01-21 2004-05-11 Medtronic Minimed, Inc. Ambulatory medical apparatus and method using a telemetry system with predefined reception listening periods
US7003336B2 (en) 2000-02-10 2006-02-21 Medtronic Minimed, Inc. Analyte sensor method of making the same
US7890295B2 (en) 2000-02-23 2011-02-15 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US6895263B2 (en) 2000-02-23 2005-05-17 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US6572542B1 (en) 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
US6405066B1 (en) 2000-03-17 2002-06-11 The Regents Of The University Of California Implantable analyte sensor
WO2001072208A2 (en) 2000-03-29 2001-10-04 University Of Virginia Patent Foundation Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US6610012B2 (en) 2000-04-10 2003-08-26 Healthetech, Inc. System and method for remote pregnancy monitoring
US6561975B1 (en) 2000-04-19 2003-05-13 Medtronic, Inc. Method and apparatus for communicating with medical device systems
US6440068B1 (en) 2000-04-28 2002-08-27 International Business Machines Corporation Measuring user health as measured by multiple diverse health measurement devices utilizing a personal storage device
AU2001263022A1 (en) 2000-05-12 2001-11-26 Therasense, Inc. Electrodes with multilayer membranes and methods of using and making the electrodes
US6442413B1 (en) 2000-05-15 2002-08-27 James H. Silver Implantable sensor
US7181261B2 (en) 2000-05-15 2007-02-20 Silver James H Implantable, retrievable, thrombus minimizing sensors
US6361503B1 (en) 2000-06-26 2002-03-26 Mediwave Star Technology, Inc. Method and system for evaluating cardiac ischemia
US6540675B2 (en) 2000-06-27 2003-04-01 Rosedale Medical, Inc. Analyte monitor
US6400974B1 (en) 2000-06-29 2002-06-04 Sensors For Medicine And Science, Inc. Implanted sensor processing system and method for processing implanted sensor output
CA2408338C (en) 2000-08-18 2009-09-08 Cygnus, Inc. Methods and devices for prediction of hypoglycemic events
US6633772B2 (en) 2000-08-18 2003-10-14 Cygnus, Inc. Formulation and manipulation of databases of analyte and associated values
EP1311189A4 (en) 2000-08-21 2005-03-09 Euro Celtique Sa Near infrared blood glucose monitoring system
WO2002030264A2 (en) 2000-10-10 2002-04-18 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
WO2002034327A2 (en) 2000-10-26 2002-05-02 Medtronic, Inc. Method and apparatus to minimize the effects of a cardiac insult
US6695860B1 (en) 2000-11-13 2004-02-24 Isense Corp. Transcutaneous sensor insertion device
US6574510B2 (en) 2000-11-30 2003-06-03 Cardiac Pacemakers, Inc. Telemetry apparatus and method for an implantable medical device
US6665558B2 (en) 2000-12-15 2003-12-16 Cardiac Pacemakers, Inc. System and method for correlation of patient health information and implant device data
US7052483B2 (en) 2000-12-19 2006-05-30 Animas Corporation Transcutaneous inserter for low-profile infusion sets
US6490479B2 (en) 2000-12-28 2002-12-03 Ge Medical Systems Information Technologies, Inc. Atrial fibrillation detection method and apparatus
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US6970529B2 (en) 2001-01-16 2005-11-29 International Business Machines Corporation Unified digital architecture
US20040197846A1 (en) 2001-01-18 2004-10-07 Linda Hockersmith Determination of glucose sensitivity and a method to manipulate blood glucose concentration
AU2002247008B2 (en) 2001-01-22 2006-02-09 F. Hoffmann-La Roche Ag Lancet device having capillary action
US20030023461A1 (en) 2001-03-14 2003-01-30 Dan Quintanilla Internet based therapy management system
US6968294B2 (en) 2001-03-15 2005-11-22 Koninklijke Philips Electronics N.V. Automatic system for monitoring person requiring care and his/her caretaker
US6622045B2 (en) 2001-03-29 2003-09-16 Pacesetter, Inc. System and method for remote programming of implantable cardiac stimulation devices
US7041468B2 (en) 2001-04-02 2006-05-09 Therasense, Inc. Blood glucose tracking apparatus and methods
US6574490B2 (en) 2001-04-11 2003-06-03 Rio Grande Medical Technologies, Inc. System for non-invasive measurement of glucose in humans
US7916013B2 (en) 2005-03-21 2011-03-29 Greatbatch Ltd. RFID detection and identification system for implantable medical devices
US6698269B2 (en) 2001-04-27 2004-03-02 Oceana Sensor Technologies, Inc. Transducer in-situ testing apparatus and method
US6676816B2 (en) 2001-05-11 2004-01-13 Therasense, Inc. Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes
US7395214B2 (en) 2001-05-11 2008-07-01 Craig P Shillingburg Apparatus, device and method for prescribing, administering and monitoring a treatment regimen for a patient
US6932894B2 (en) 2001-05-15 2005-08-23 Therasense, Inc. Biosensor membranes composed of polymers containing heterocyclic nitrogens
US6549796B2 (en) 2001-05-25 2003-04-15 Lifescan, Inc. Monitoring analyte concentration using minimally invasive devices
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
US7179226B2 (en) 2001-06-21 2007-02-20 Animas Corporation System and method for managing diabetes
WO2003000127A2 (en) 2001-06-22 2003-01-03 Cygnus, Inc. Method for improving the performance of an analyte monitoring system
US7044911B2 (en) 2001-06-29 2006-05-16 Philometron, Inc. Gateway platform for biological monitoring and delivery of therapeutic compounds
US20030208113A1 (en) 2001-07-18 2003-11-06 Mault James R Closed loop glycemic index system
US6754516B2 (en) 2001-07-19 2004-06-22 Nellcor Puritan Bennett Incorporated Nuisance alarm reductions in a physiological monitor
US6702857B2 (en) 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US6544212B2 (en) 2001-07-31 2003-04-08 Roche Diagnostics Corporation Diabetes management system
WO2003014735A1 (en) 2001-08-03 2003-02-20 General Hospital Corporation System, process and diagnostic arrangement establishing and monitoring medication doses for patients
CN1311781C (en) 2001-08-20 2007-04-25 因弗内斯医疗有限公司 Wireless diabetes management devices and methods for using the same
CA2459408A1 (en) 2001-08-28 2003-03-13 Medtronic, Inc. Medical device for treating cardiac mechanical dysfunction by electrical stimulation
US6827702B2 (en) 2001-09-07 2004-12-07 Medtronic Minimed, Inc. Safety limits for closed-loop infusion pump control
US7052591B2 (en) 2001-09-21 2006-05-30 Therasense, Inc. Electrodeposition of redox polymers and co-electrodeposition of enzymes by coordinative crosslinking
US6830562B2 (en) 2001-09-27 2004-12-14 Unomedical A/S Injector device for placing a subcutaneous infusion set
US6731985B2 (en) 2001-10-16 2004-05-04 Pacesetter, Inc. Implantable cardiac stimulation system and method for automatic capture verification calibration
US7854230B2 (en) 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
US6636857B2 (en) 2001-12-18 2003-10-21 Bluecurrent, Inc. Method and system for web-based asset management
US7204823B2 (en) 2001-12-19 2007-04-17 Medtronic Minimed, Inc. Medication delivery system and monitor
US7082334B2 (en) 2001-12-19 2006-07-25 Medtronic, Inc. System and method for transmission of medical and like data from a patient to a dedicated internet website
US7729776B2 (en) 2001-12-19 2010-06-01 Cardiac Pacemakers, Inc. Implantable medical device with two or more telemetry systems
US20050027182A1 (en) 2001-12-27 2005-02-03 Uzair Siddiqui System for monitoring physiological characteristics
US20080255438A1 (en) 2001-12-27 2008-10-16 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US7399277B2 (en) 2001-12-27 2008-07-15 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US7022072B2 (en) 2001-12-27 2006-04-04 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US7184820B2 (en) 2002-01-25 2007-02-27 Subqiview, Inc. Tissue monitoring system for intravascular infusion
US20030144711A1 (en) 2002-01-29 2003-07-31 Neuropace, Inc. Systems and methods for interacting with an implantable medical device
US6985773B2 (en) 2002-02-07 2006-01-10 Cardiac Pacemakers, Inc. Methods and apparatuses for implantable medical device telemetry power management
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US8364229B2 (en) 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US20030212379A1 (en) 2002-02-26 2003-11-13 Bylund Adam David Systems and methods for remotely controlling medication infusion and analyte monitoring
AU2003213638A1 (en) 2002-02-26 2003-09-09 Sterling Medivations, Inc. Insertion device for an insertion set and method of using the same
US7043305B2 (en) 2002-03-06 2006-05-09 Cardiac Pacemakers, Inc. Method and apparatus for establishing context among events and optimizing implanted medical device performance
US7468032B2 (en) 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US6998247B2 (en) 2002-03-08 2006-02-14 Sensys Medical, Inc. Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers
US6936006B2 (en) 2002-03-22 2005-08-30 Novo Nordisk, A/S Atraumatic insertion of a subcutaneous device
US7027848B2 (en) 2002-04-04 2006-04-11 Inlight Solutions, Inc. Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte
US7410468B2 (en) 2002-04-19 2008-08-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7153265B2 (en) 2002-04-22 2006-12-26 Medtronic Minimed, Inc. Anti-inflammatory biosensor for reduced biofouling and enhanced sensor performance
US20050177398A1 (en) 2002-04-25 2005-08-11 Motokazu Watanabe Dosage determination supporting device, injector, and health management supporting system
US7226978B2 (en) 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US6865407B2 (en) 2002-07-11 2005-03-08 Optical Sensors, Inc. Calibration technique for non-invasive medical devices
US20040010207A1 (en) 2002-07-15 2004-01-15 Flaherty J. Christopher Self-contained, automatic transcutaneous physiologic sensing system
AU2003302720B9 (en) 2002-07-19 2008-08-21 Smiths Detection-Pasadena, Inc. Non-specific sensor array detectors
US7278983B2 (en) 2002-07-24 2007-10-09 Medtronic Minimed, Inc. Physiological monitoring device for controlling a medication infusion device
ES2456068T3 (en) 2002-08-13 2014-04-21 University Of Virginia Patent Foundation Method, system and software product for glycemia self-monitoring (SMBG) data processing to improve diabetic self-management
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
US7404796B2 (en) 2004-03-01 2008-07-29 Becton Dickinson And Company System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
US7192405B2 (en) 2002-09-30 2007-03-20 Becton, Dickinson And Company Integrated lancet and bodily fluid sensor
DK1575656T3 (en) 2002-10-11 2009-09-14 Becton Dickinson Co Insulin delivery system with sensor
US7029443B2 (en) 2002-10-21 2006-04-18 Pacesetter, Inc. System and method for monitoring blood glucose levels using an implantable medical device
US7381184B2 (en) 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
US7572237B2 (en) 2002-11-06 2009-08-11 Abbott Diabetes Care Inc. Automatic biological analyte testing meter with integrated lancing device and methods of use
US7009511B2 (en) 2002-12-17 2006-03-07 Cardiac Pacemakers, Inc. Repeater device for communications with an implantable medical device
US20040122353A1 (en) 2002-12-19 2004-06-24 Medtronic Minimed, Inc. Relay device for transferring information between a sensor system and a fluid delivery system
EP1578262A4 (en) 2002-12-31 2007-12-05 Therasense Inc Continuous glucose monitoring system and methods of use
US7396330B2 (en) 2003-01-07 2008-07-08 Triage Data Networks Wireless, internet-based medical-diagnostic system
US7207947B2 (en) 2003-01-10 2007-04-24 Pacesetter, Inc. System and method for detecting circadian states using an implantable medical device
WO2004084820A2 (en) 2003-03-19 2004-10-07 Harry Hebblewhite Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients
US7134999B2 (en) 2003-04-04 2006-11-14 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
WO2004093648A2 (en) 2003-04-18 2004-11-04 Insulet Corporation User interface for infusion pump remote controller and method of using the same
US7103412B1 (en) 2003-05-02 2006-09-05 Pacesetter, Inc. Implantable cardiac stimulation device and method for detecting asymptomatic diabetes
US7875293B2 (en) 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
US7258673B2 (en) 2003-06-06 2007-08-21 Lifescan, Inc Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
US20050016276A1 (en) 2003-06-06 2005-01-27 Palo Alto Sensor Technology Innovation Frequency encoding of resonant mass sensors
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
EP1636579A4 (en) 2003-06-10 2011-10-05 Smiths Detection Inc Sensor arrangement
US20040254433A1 (en) 2003-06-12 2004-12-16 Bandis Steven D. Sensor introducer system, apparatus and method
US7142911B2 (en) 2003-06-26 2006-11-28 Pacesetter, Inc. Method and apparatus for monitoring drug effects on cardiac electrical signals using an implantable cardiac stimulation device
US7510564B2 (en) 2003-06-27 2009-03-31 Abbott Diabetes Care Inc. Lancing device
US7242981B2 (en) 2003-06-30 2007-07-10 Codman Neuro Sciences Sárl System and method for controlling an implantable medical device subject to magnetic field or radio frequency exposure
WO2005007223A2 (en) 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
US7366556B2 (en) 2003-12-05 2008-04-29 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7424318B2 (en) 2003-12-05 2008-09-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7467003B2 (en) 2003-12-05 2008-12-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
WO2005012873A2 (en) 2003-07-25 2005-02-10 Dexcom, Inc. Electrode systems for electrochemical sensors
US7761130B2 (en) 2003-07-25 2010-07-20 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US20050176136A1 (en) 2003-11-19 2005-08-11 Dexcom, Inc. Afinity domain for analyte sensor
EP1648298A4 (en) 2003-07-25 2010-01-13 Dexcom Inc Oxygen enhancing membrane systems for implantable devices
US7460898B2 (en) 2003-12-05 2008-12-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7108778B2 (en) 2003-07-25 2006-09-19 Dexcom, Inc. Electrochemical sensors including electrode systems with increased oxygen generation
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8060173B2 (en) 2003-08-01 2011-11-15 Dexcom, Inc. System and methods for processing analyte sensor data
US7494465B2 (en) 2004-07-13 2009-02-24 Dexcom, Inc. Transcutaneous analyte sensor
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US7986986B2 (en) 2003-08-01 2011-07-26 Dexcom, Inc. System and methods for processing analyte sensor data
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US8626257B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. Analyte sensor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8140168B2 (en) 2003-10-02 2012-03-20 Medtronic, Inc. External power source for an implantable medical device having an adjustable carrier frequency and system and method related therefore
US7203549B2 (en) 2003-10-02 2007-04-10 Medtronic, Inc. Medical device programmer with internal antenna and display
WO2005037092A1 (en) 2003-10-13 2005-04-28 Novo Nordisk A/S Apparatus and method for determining a physiological condition
US7148803B2 (en) 2003-10-24 2006-12-12 Symbol Technologies, Inc. Radio frequency identification (RFID) based sensor networks
US20050090607A1 (en) 2003-10-28 2005-04-28 Dexcom, Inc. Silicone composition for biocompatible membrane
GB2406023B (en) 2003-10-29 2005-08-10 Innovision Res & Tech Plc RFID apparatus
US6928380B2 (en) 2003-10-30 2005-08-09 International Business Machines Corporation Thermal measurements of electronic devices during operation
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US7419573B2 (en) 2003-11-06 2008-09-02 3M Innovative Properties Company Circuit for electrochemical sensor strip
WO2005051170A2 (en) 2003-11-19 2005-06-09 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US8774886B2 (en) 2006-10-04 2014-07-08 Dexcom, Inc. Analyte sensor
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8425417B2 (en) 2003-12-05 2013-04-23 Dexcom, Inc. Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device
EP2239567B1 (en) 2003-12-05 2015-09-02 DexCom, Inc. Calibration techniques for a continuous analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8425416B2 (en) 2006-10-04 2013-04-23 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US20080200788A1 (en) 2006-10-04 2008-08-21 Dexcorn, Inc. Analyte sensor
US20080197024A1 (en) 2003-12-05 2008-08-21 Dexcom, Inc. Analyte sensor
US8364230B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
EP3241490A1 (en) 2003-12-08 2017-11-08 DexCom, Inc. Systems and methods for improving electrochemical analyte sensors
EP2329763B1 (en) 2003-12-09 2017-06-21 DexCom, Inc. Signal processing for continuous analyte sensor
US7076300B1 (en) 2003-12-24 2006-07-11 Pacesetter, Inc. Implantable cardiac stimulation device and method that discriminates between and treats atrial tachycardia and atrial fibrillation
US7384397B2 (en) 2003-12-30 2008-06-10 Medtronic Minimed, Inc. System and method for sensor recalibration
US7637868B2 (en) 2004-01-12 2009-12-29 Dexcom, Inc. Composite material for implantable device
US8136735B2 (en) 2004-01-23 2012-03-20 Semiconductor Energy Laboratory Co., Ltd. ID label, ID card, and ID tag
US7580812B2 (en) 2004-01-28 2009-08-25 Honeywell International Inc. Trending system and method using window filtering
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US7364592B2 (en) 2004-02-12 2008-04-29 Dexcom, Inc. Biointerface membrane with macro-and micro-architecture
WO2005089103A2 (en) 2004-02-17 2005-09-29 Therasense, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
JP4611372B2 (en) 2004-02-26 2011-01-12 ダイアベティス ツールズ スウェーデン アーベー Metabolic monitoring, method and apparatus for displaying conditions related to the health of a subject
DE102004011135A1 (en) 2004-03-08 2005-09-29 Disetronic Licensing Ag Method and apparatus for calculating a bolus amount
US7228182B2 (en) 2004-03-15 2007-06-05 Cardiac Pacemakers, Inc. Cryptographic authentication for telemetry with an implantable medical device
EP1734858B1 (en) 2004-03-22 2014-07-09 BodyMedia, Inc. Non-invasive temperature monitoring device
EP1735729A2 (en) 2004-03-26 2006-12-27 Novo Nordisk A/S Device for displaying data relevant for a diabetic patient
US6971274B2 (en) 2004-04-02 2005-12-06 Sierra Instruments, Inc. Immersible thermal mass flow meter
US7815569B2 (en) 2004-04-21 2010-10-19 University Of Virginia Patent Foundation Method, system and computer program product for evaluating the accuracy of blood glucose monitoring sensors/devices
US7324850B2 (en) 2004-04-29 2008-01-29 Cardiac Pacemakers, Inc. Method and apparatus for communication between a handheld programmer and an implantable medical device
US20050245799A1 (en) 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US8277713B2 (en) 2004-05-03 2012-10-02 Dexcom, Inc. Implantable analyte sensor
US7125382B2 (en) 2004-05-20 2006-10-24 Digital Angel Corporation Embedded bio-sensor system
US7118667B2 (en) 2004-06-02 2006-10-10 Jin Po Lee Biosensors having improved sample application and uses thereof
CA2572455C (en) 2004-06-04 2014-10-28 Therasense, Inc. Diabetes care host-client architecture and data management system
US7565197B2 (en) 2004-06-18 2009-07-21 Medtronic, Inc. Conditional requirements for remote medical device programming
US7623988B2 (en) 2004-06-23 2009-11-24 Cybiocare Inc. Method and apparatus for the monitoring of clinical states
US7233822B2 (en) 2004-06-29 2007-06-19 Medtronic, Inc. Combination of electrogram and intra-cardiac pressure to discriminate between fibrillation and tachycardia
US20060001538A1 (en) 2004-06-30 2006-01-05 Ulrich Kraft Methods of monitoring the concentration of an analyte
US20060015020A1 (en) 2004-07-06 2006-01-19 Dexcom, Inc. Systems and methods for manufacture of an analyte-measuring device including a membrane system
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US20060270922A1 (en) 2004-07-13 2006-11-30 Brauker James H Analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US20080242961A1 (en) 2004-07-13 2008-10-02 Dexcom, Inc. Transcutaneous analyte sensor
US7857760B2 (en) 2004-07-13 2010-12-28 Dexcom, Inc. Analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US7310544B2 (en) 2004-07-13 2007-12-18 Dexcom, Inc. Methods and systems for inserting a transcutaneous analyte sensor
US7344500B2 (en) 2004-07-27 2008-03-18 Medtronic Minimed, Inc. Sensing system with auxiliary display
US8313433B2 (en) 2004-08-06 2012-11-20 Medtronic Minimed, Inc. Medical data management system and process
JP5032321B2 (en) 2004-08-31 2012-09-26 ライフスキャン・スコットランド・リミテッド Manufacturing method of automatic calibration sensor
EP1788930A1 (en) 2004-09-03 2007-05-30 Novo Nordisk A/S A method of calibrating a system for measuring the concentration of substances in body and an apparatus for exercising the method
ATE490724T1 (en) 2004-11-02 2010-12-15 Medtronic Inc DEVICE FOR DATA RETENTION IN AN IMPLANTABLE MEDICAL DEVICE
US7237712B2 (en) 2004-12-01 2007-07-03 Alfred E. Mann Foundation For Scientific Research Implantable device and communication integrated circuit implementable therein
JPWO2006070827A1 (en) 2004-12-28 2008-06-12 新世代株式会社 Health care support system and recording medium
US20070027381A1 (en) 2005-07-29 2007-02-01 Therasense, Inc. Inserter and methods of use
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US20090082693A1 (en) 2004-12-29 2009-03-26 Therasense, Inc. Method and apparatus for providing temperature sensor module in a data communication system
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US20060166629A1 (en) 2005-01-24 2006-07-27 Therasense, Inc. Method and apparatus for providing EMC Class-B compliant RF transmitter for data monitoring an detection systems
US7297114B2 (en) 2005-01-25 2007-11-20 Pacesetter, Inc. System and method for distinguishing among cardiac ischemia, hypoglycemia and hyperglycemia using an implantable medical device
US20060173260A1 (en) 2005-01-31 2006-08-03 Gmms Ltd System, device and method for diabetes treatment and monitoring
US7547281B2 (en) 2005-02-01 2009-06-16 Medtronic Minimed, Inc. Algorithm sensor augmented bolus estimator for semi-closed loop infusion system
US7499002B2 (en) 2005-02-08 2009-03-03 International Business Machines Corporation Retractable string interface for stationary and portable devices
US7545272B2 (en) 2005-02-08 2009-06-09 Therasense, Inc. RF tag on test strips, test strip vials and boxes
US20090076360A1 (en) 2007-09-13 2009-03-19 Dexcom, Inc. Transcutaneous analyte sensor
US20070071681A1 (en) 2005-03-15 2007-03-29 Entelos, Inc. Apparatus and method for computer modeling type 1 diabetes
US7889069B2 (en) 2005-04-01 2011-02-15 Codman & Shurtleff, Inc. Wireless patient monitoring system
WO2006110193A2 (en) 2005-04-08 2006-10-19 Dexcom, Inc. Cellulosic-based interference domain for an analyte sensor
US7270633B1 (en) 2005-04-22 2007-09-18 Cardiac Pacemakers, Inc. Ambulatory repeater for use in automated patient care and method thereof
DE102005019306B4 (en) 2005-04-26 2011-09-01 Disetronic Licensing Ag Energy-optimized data transmission of a medical device
US7590443B2 (en) 2005-04-27 2009-09-15 Pacesetter, Inc System and method for detecting hypoglycemia based on a paced depolarization integral using an implantable medical device
US20060247985A1 (en) 2005-04-29 2006-11-02 Therasense, Inc. Method and system for monitoring consumable item usage and providing replenishment thereof
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US8700157B2 (en) 2005-04-29 2014-04-15 Medtronic, Inc. Telemetry head programmer for implantable medical device and system and method
US7604178B2 (en) 2005-05-11 2009-10-20 Intelleflex Corporation Smart tag activation
JP5037496B2 (en) 2005-05-13 2012-09-26 トラスティーズ オブ ボストン ユニバーシティ Fully automatic control system for type 1 diabetes
US7541935B2 (en) 2005-05-19 2009-06-02 Proacticare Llc System and methods for monitoring caregiver performance
DE602006016266D1 (en) 2005-06-02 2010-09-30 Isense Corp USING MULTIPLE DATA POINTS AND FILTERING IN AN ANALYTICAL SENSOR
US20060272652A1 (en) 2005-06-03 2006-12-07 Medtronic Minimed, Inc. Virtual patient software system for educating and treating individuals with diabetes
US20070033074A1 (en) 2005-06-03 2007-02-08 Medtronic Minimed, Inc. Therapy management system
US20070016449A1 (en) 2005-06-29 2007-01-18 Gary Cohen Flexible glucose analysis using varying time report deltas and configurable glucose target ranges
CN101860089B (en) 2005-07-12 2013-02-06 麻省理工学院 Wireless non-radiative energy transfer
EP1758039A1 (en) 2005-08-27 2007-02-28 Roche Diagnostics GmbH Communication adaptor for portable medical or therapeutical devices
EP1921980A4 (en) 2005-08-31 2010-03-10 Univ Virginia Improving the accuracy of continuous glucose sensors
JP2009506852A (en) 2005-09-09 2009-02-19 エフ.ホフマン−ラ ロシュ アーゲー System, tool, apparatus and program for diabetes treatment
US7725148B2 (en) 2005-09-23 2010-05-25 Medtronic Minimed, Inc. Sensor with layered electrodes
US9072476B2 (en) 2005-09-23 2015-07-07 Medtronic Minimed, Inc. Flexible sensor apparatus
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
WO2007056592A2 (en) 2005-11-08 2007-05-18 M2 Medical A/S Method and system for manual and autonomous control of an infusion pump
US20070173706A1 (en) 2005-11-11 2007-07-26 Isense Corporation Method and apparatus for insertion of a sensor
WO2007062173A1 (en) 2005-11-22 2007-05-31 Vocollect Healthcare Systems, Inc. Advanced diabetes management system (adms)
US7941200B2 (en) 2005-12-08 2011-05-10 Roche Diagnostics Operations, Inc. System and method for determining drug administration information
EP1968432A4 (en) 2005-12-28 2009-10-21 Abbott Diabetes Care Inc Medical device insertion
US8515518B2 (en) 2005-12-28 2013-08-20 Abbott Diabetes Care Inc. Analyte monitoring
US8160670B2 (en) 2005-12-28 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent
US8102789B2 (en) 2005-12-29 2012-01-24 Medtronic, Inc. System and method for synchronous wireless communication with a medical device
US7574266B2 (en) 2006-01-19 2009-08-11 Medtronic, Inc. System and method for telemetry with an implantable medical device
US20070179349A1 (en) 2006-01-19 2007-08-02 Hoyme Kenneth P System and method for providing goal-oriented patient management based upon comparative population data analysis
US7736310B2 (en) 2006-01-30 2010-06-15 Abbott Diabetes Care Inc. On-body medical device securement
CN101360450A (en) * 2006-02-27 2009-02-04 爱德华兹生命科学公司 Flux limiting membrane for intravenous amperometric biosensor
US7981034B2 (en) 2006-02-28 2011-07-19 Abbott Diabetes Care Inc. Smart messages and alerts for an infusion delivery and management system
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
EP1991110B1 (en) 2006-03-09 2018-11-07 DexCom, Inc. Systems and methods for processing analyte sensor data
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US7618369B2 (en) 2006-10-02 2009-11-17 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US7630748B2 (en) 2006-10-25 2009-12-08 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US9326709B2 (en) 2010-03-10 2016-05-03 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US7359837B2 (en) 2006-04-27 2008-04-15 Medtronic, Inc. Peak data retention of signal data in an implantable medical device
US20070253021A1 (en) 2006-04-28 2007-11-01 Medtronic Minimed, Inc. Identification of devices in a medical device network and wireless data communication techniques utilizing device identifiers
US20070258395A1 (en) 2006-04-28 2007-11-08 Medtronic Minimed, Inc. Wireless data communication protocols for a medical device network
EP2014105B1 (en) 2006-05-02 2013-06-26 3M Innovative Properties Company A telecommunication enclosure monitoring system
GB0608829D0 (en) 2006-05-04 2006-06-14 Husheer Shamus L G In-situ measurement of physical parameters
DE102006023213B3 (en) 2006-05-17 2007-09-27 Siemens Ag Sensor operating method, involves detecting recording and evaluation device during order and non-order functions of monitoring device in check mode, and watching occurrence of results in mode by sensor, which automatically leaves mode
DE102006025485B4 (en) 2006-05-30 2008-03-20 Polylc Gmbh & Co. Kg Antenna arrangement and its use
US20080071158A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
US8098159B2 (en) 2006-06-09 2012-01-17 Intelleflex Corporation RF device comparing DAC output to incoming signal for selectively performing an action
US7796038B2 (en) 2006-06-12 2010-09-14 Intelleflex Corporation RFID sensor tag with manual modes and functions
US20080177149A1 (en) 2006-06-16 2008-07-24 Stefan Weinert System and method for collecting patient information from which diabetes therapy may be determined
US20070299617A1 (en) 2006-06-27 2007-12-27 Willis John P Biofouling self-compensating biosensor
US20080004601A1 (en) 2006-06-28 2008-01-03 Abbott Diabetes Care, Inc. Analyte Monitoring and Therapy Management System and Methods Therefor
US20090105560A1 (en) 2006-06-28 2009-04-23 David Solomon Lifestyle and eating advisor based on physiological and biological rhythm monitoring
US9119582B2 (en) 2006-06-30 2015-09-01 Abbott Diabetes Care, Inc. Integrated analyte sensor and infusion device and methods therefor
US8932216B2 (en) 2006-08-07 2015-01-13 Abbott Diabetes Care Inc. Method and system for providing data management in integrated analyte monitoring and infusion system
GB0616331D0 (en) 2006-08-16 2006-09-27 Innovision Res & Tech Plc Near Field RF Communicators And Near Field Communications Enabled Devices
US20090256572A1 (en) 2008-04-14 2009-10-15 Mcdowell Andrew F Tuning Low-Inductance Coils at Low Frequencies
US9056165B2 (en) 2006-09-06 2015-06-16 Medtronic Minimed, Inc. Intelligent therapy recommendation algorithm and method of using the same
US20080071328A1 (en) 2006-09-06 2008-03-20 Medtronic, Inc. Initiating medical system communications
US7779332B2 (en) 2006-09-25 2010-08-17 Alfred E. Mann Foundation For Scientific Research Rotationally invariant non-coherent burst coding
US8562528B2 (en) 2006-10-04 2013-10-22 Dexcom, Inc. Analyte sensor
US8449464B2 (en) 2006-10-04 2013-05-28 Dexcom, Inc. Analyte sensor
US8275438B2 (en) 2006-10-04 2012-09-25 Dexcom, Inc. Analyte sensor
US8478377B2 (en) 2006-10-04 2013-07-02 Dexcom, Inc. Analyte sensor
US7831287B2 (en) 2006-10-04 2010-11-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8447376B2 (en) 2006-10-04 2013-05-21 Dexcom, Inc. Analyte sensor
US8298142B2 (en) 2006-10-04 2012-10-30 Dexcom, Inc. Analyte sensor
US8126728B2 (en) 2006-10-24 2012-02-28 Medapps, Inc. Systems and methods for processing and transmittal of medical data through an intermediary device
CA2667639A1 (en) 2006-10-26 2008-05-02 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
EP1918837A1 (en) 2006-10-31 2008-05-07 F. Hoffmann-La Roche AG Method for processing a chronological sequence of measurements of a time dependent parameter
US20080119705A1 (en) 2006-11-17 2008-05-22 Medtronic Minimed, Inc. Systems and Methods for Diabetes Management Using Consumer Electronic Devices
US20080139910A1 (en) 2006-12-06 2008-06-12 Metronic Minimed, Inc. Analyte sensor and method of using the same
KR100833511B1 (en) 2006-12-08 2008-05-29 한국전자통신연구원 Passive tag with volatile memory
US8120493B2 (en) 2006-12-20 2012-02-21 Intel Corporation Direct communication in antenna devices
US20080154513A1 (en) 2006-12-21 2008-06-26 University Of Virginia Patent Foundation Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes
US20080161666A1 (en) 2006-12-29 2008-07-03 Abbott Diabetes Care, Inc. Analyte devices and methods
CA2678109C (en) 2007-01-15 2020-05-26 Deka Products Limited Partnership Device and method for food management
US8098160B2 (en) 2007-01-22 2012-01-17 Cisco Technology, Inc. Method and system for remotely provisioning and/or configuring a device
US10154804B2 (en) 2007-01-31 2018-12-18 Medtronic Minimed, Inc. Model predictive method and system for controlling and supervising insulin infusion
US9597019B2 (en) 2007-02-09 2017-03-21 Lifescan, Inc. Method of ensuring date and time on a test meter is accurate
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US7659823B1 (en) 2007-03-20 2010-02-09 At&T Intellectual Property Ii, L.P. Tracking variable conditions using radio frequency identification
US8140142B2 (en) 2007-04-14 2012-03-20 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
WO2008130896A1 (en) 2007-04-14 2008-10-30 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
US9615780B2 (en) 2007-04-14 2017-04-11 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
EP4108162A1 (en) 2007-04-14 2022-12-28 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
EP2146625B1 (en) 2007-04-14 2019-08-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
WO2008143943A1 (en) 2007-05-14 2008-11-27 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20080312845A1 (en) 2007-05-14 2008-12-18 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7996158B2 (en) 2007-05-14 2011-08-09 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20080300572A1 (en) 2007-06-01 2008-12-04 Medtronic Minimed, Inc. Wireless monitor for a personal medical device system
US8072310B1 (en) 2007-06-05 2011-12-06 Pulsed Indigo Inc. System for detecting and measuring parameters of passive transponders
EP2152350A4 (en) 2007-06-08 2013-03-27 Dexcom Inc Integrated medicament delivery device for use with continuous analyte sensor
US20080312518A1 (en) 2007-06-14 2008-12-18 Arkal Medical, Inc On-demand analyte monitor and method of use
CN107411754A (en) 2007-06-15 2017-12-01 霍夫曼-拉罗奇有限公司 The visualization of the parameter measured on human body
US9754078B2 (en) 2007-06-21 2017-09-05 Immersion Corporation Haptic health feedback monitoring
KR101347008B1 (en) 2007-06-27 2014-01-02 에프. 호프만-라 로슈 아게 System and method for developing patient specific therapies based on modeling of patient physiology
WO2009002622A2 (en) 2007-06-27 2008-12-31 F. Hoffman-La Roche Ag Patient information input interface for a therapy system
DK3460644T3 (en) 2007-06-29 2021-03-22 Hoffmann La Roche Electronic blood glucose meter
US20090036760A1 (en) 2007-07-31 2009-02-05 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US7768386B2 (en) 2007-07-31 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
WO2009018058A1 (en) 2007-07-31 2009-02-05 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US7731658B2 (en) 2007-08-16 2010-06-08 Cardiac Pacemakers, Inc. Glycemic control monitoring using implantable medical device
US9968742B2 (en) 2007-08-29 2018-05-15 Medtronic Minimed, Inc. Combined sensor and infusion set using separated sites
US20090063402A1 (en) 2007-08-31 2009-03-05 Abbott Diabetes Care, Inc. Method and System for Providing Medication Level Determination
US20090085768A1 (en) 2007-10-02 2009-04-02 Medtronic Minimed, Inc. Glucose sensor transceiver
DE102007047351A1 (en) 2007-10-02 2009-04-09 B. Braun Melsungen Ag System and method for monitoring and controlling blood glucose levels
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US7783442B2 (en) 2007-10-31 2010-08-24 Medtronic Minimed, Inc. System and methods for calibrating physiological characteristic sensors
US8098201B2 (en) 2007-11-29 2012-01-17 Electronics & Telecommunications Research Institute Radio frequency identification tag and radio frequency identification tag antenna
US8103241B2 (en) 2007-12-07 2012-01-24 Roche Diagnostics Operations, Inc. Method and system for wireless device communication
US8290559B2 (en) 2007-12-17 2012-10-16 Dexcom, Inc. Systems and methods for processing sensor data
US20090164239A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Dynamic Display Of Glucose Information
US20090164251A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Method and apparatus for providing treatment profile management
EP2235660B1 (en) 2008-01-15 2015-07-08 Corning Cable Systems LLC Rfid systems and methods for automatically detecting and/or directing the physical configuration of a complex system
DE102008008072A1 (en) 2008-01-29 2009-07-30 Balluff Gmbh sensor
WO2009097450A1 (en) 2008-01-30 2009-08-06 Dexcom. Inc. Continuous cardiac marker sensor system
WO2009105337A2 (en) 2008-02-20 2009-08-27 Dexcom, Inc. Continuous medicament sensor system for in vivo use
US8229535B2 (en) 2008-02-21 2012-07-24 Dexcom, Inc. Systems and methods for blood glucose monitoring and alert delivery
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US20090242399A1 (en) 2008-03-25 2009-10-01 Dexcom, Inc. Analyte sensor
US20090247856A1 (en) 2008-03-28 2009-10-01 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8600682B2 (en) 2008-04-04 2013-12-03 Hygieia, Inc. Apparatus for optimizing a patient's insulin dosage regimen
US20090267765A1 (en) 2008-04-29 2009-10-29 Jack Greene Rfid to prevent reprocessing
US8102021B2 (en) 2008-05-12 2012-01-24 Sychip Inc. RF devices
CA2724446C (en) 2008-05-14 2017-04-04 Espenusa Holding, Llc Physical activity monitor and data collection unit
US8610577B2 (en) 2008-05-20 2013-12-17 Deka Products Limited Partnership RFID system
US8117481B2 (en) 2008-06-06 2012-02-14 Roche Diagnostics International Ag Apparatus and method for processing wirelessly communicated information within an electronic device
US8132037B2 (en) 2008-06-06 2012-03-06 Roche Diagnostics International Ag Apparatus and method for processing wirelessly communicated data and clock information within an electronic device
US8131365B2 (en) 2008-07-09 2012-03-06 Cardiac Pacemakers, Inc. Event-based battery monitor for implantable devices
US8111042B2 (en) 2008-08-05 2012-02-07 Broadcom Corporation Integrated wireless resonant power charging and communication channel
US8432070B2 (en) 2008-08-25 2013-04-30 Qualcomm Incorporated Passive receivers for wireless power transmission
US8094009B2 (en) 2008-08-27 2012-01-10 The Invention Science Fund I, Llc Health-related signaling via wearable items
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US20100057040A1 (en) 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Robust Closed Loop Control And Methods
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US8102154B2 (en) 2008-09-04 2012-01-24 Medtronic Minimed, Inc. Energy source isolation and protection circuit for an electronic device
WO2010030609A1 (en) 2008-09-09 2010-03-18 Vivomedical, Inc. Sweat collection devices for glucose measurement
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US8098161B2 (en) 2008-12-01 2012-01-17 Raytheon Company Radio frequency identification inlay with improved readability
US8150516B2 (en) 2008-12-11 2012-04-03 Pacesetter, Inc. Systems and methods for operating an implantable device for medical procedures
US9320470B2 (en) 2008-12-31 2016-04-26 Medtronic Minimed, Inc. Method and/or system for sensor artifact filtering
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
DK3714788T3 (en) 2009-02-26 2023-04-17 Abbott Diabetes Care Inc Method for manufacturing improved analyte sensors
US8062249B2 (en) 2009-03-31 2011-11-22 Abbott Diabetes Care Inc. Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
WO2010121229A1 (en) 2009-04-16 2010-10-21 Abbott Diabetes Care Inc. Analyte sensor calibration management
WO2010127052A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Dynamic analyte sensor calibration based on sensor stability profile
US8483967B2 (en) 2009-04-29 2013-07-09 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US8368556B2 (en) 2009-04-29 2013-02-05 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8124452B2 (en) 2009-06-14 2012-02-28 Terepac Corporation Processes and structures for IC fabrication
US9237864B2 (en) 2009-07-02 2016-01-19 Dexcom, Inc. Analyte sensors and methods of manufacturing same
US9792408B2 (en) 2009-07-02 2017-10-17 Covidien Lp Method and apparatus to detect transponder tagged objects and to communicate with medical telemetry devices, for example during medical procedures
ES2952361T3 (en) 2009-08-31 2023-10-31 Abbott Diabetes Care Inc Displays for a medical device
US8093991B2 (en) 2009-09-16 2012-01-10 Greatbatch Ltd. RFID detection and identification system for implantable medical devices
CN102724913A (en) 2009-09-30 2012-10-10 德克斯康公司 Transcutaneous analyte sensor
EP2494323A4 (en) 2009-10-30 2014-07-16 Abbott Diabetes Care Inc Method and apparatus for detecting false hypoglycemic conditions
US9949672B2 (en) 2009-12-17 2018-04-24 Ascensia Diabetes Care Holdings Ag Apparatus, systems and methods for determining and displaying pre-event and post-event analyte concentration levels
US20110184268A1 (en) 2010-01-22 2011-07-28 Abbott Diabetes Care Inc. Method, Device and System for Providing Analyte Sensor Calibration
US8579879B2 (en) 2010-02-19 2013-11-12 Medtronic Minimed, Inc. Closed-loop glucose control startup
US20110208027A1 (en) 2010-02-23 2011-08-25 Roche Diagnostics Operations, Inc. Methods And Systems For Providing Therapeutic Guidelines To A Person Having Diabetes
US9336353B2 (en) 2010-06-25 2016-05-10 Dexcom, Inc. Systems and methods for communicating sensor data between communication devices of a glucose monitoring system
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
DK2621339T3 (en) 2010-09-29 2020-02-24 Dexcom Inc ADVANCED SYSTEM FOR CONTINUOUS ANALYTICAL MONITORING
EP3744249A1 (en) 2010-10-27 2020-12-02 Dexcom, Inc. Continuous analyte monitor data recording device operable in a blinded mode

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7016713B2 (en) * 1995-08-09 2006-03-21 Inlight Solutions, Inc. Non-invasive determination of direction and rate of change of an analyte

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bremer et al., Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies, DIABETES TECHNOLOGY & THERAPEUTICS, Volume 3, Number 3, 2001 *
Lodwig et al., Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria, DIABETES TECHNOLOGY & THERAPEUTICS Volume 5, Number 4, 2003 *
Panteleon et al, The Role of the Independent Variable to Glucose Sensor Calibration, DIABETES TECHNOLOGY & THERAPEUTICS Volume 5, Number 3, 2003 *

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11627900B2 (en) 2003-12-05 2023-04-18 Dexcom, Inc. Analyte sensor
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US11020031B1 (en) 2003-12-05 2021-06-01 Dexcom, Inc. Analyte sensor
US8718958B2 (en) 2006-10-26 2014-05-06 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US9801571B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8571808B2 (en) 2007-05-14 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10143409B2 (en) 2007-05-14 2018-12-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10653344B2 (en) 2007-05-14 2020-05-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10820841B2 (en) 2007-05-14 2020-11-03 Abbot Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10045720B2 (en) 2007-05-14 2018-08-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9483608B2 (en) 2007-05-14 2016-11-01 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9804150B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8583205B2 (en) 2008-03-28 2013-11-12 Abbott Diabetes Care Inc. Analyte sensor calibration management
US10980461B2 (en) 2008-11-07 2021-04-20 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10827954B2 (en) 2009-07-23 2020-11-10 Abbott Diabetes Care Inc. Continuous analyte measurement systems and systems and methods for implanting them
US9795326B2 (en) 2009-07-23 2017-10-24 Abbott Diabetes Care Inc. Continuous analyte measurement systems and systems and methods for implanting them
US9936910B2 (en) 2009-07-31 2018-04-10 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring and therapy management system accuracy
US10660554B2 (en) 2009-07-31 2020-05-26 Abbott Diabetes Care Inc. Methods and devices for analyte monitoring calibration
US11234625B2 (en) 2009-07-31 2022-02-01 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring and therapy management system accuracy
US10123752B2 (en) 2009-08-31 2018-11-13 Abbott Diabetes Care Inc. Displays for a medical device
US10881355B2 (en) 2009-08-31 2021-01-05 Abbott Diabetes Care Inc. Displays for a medical device
US10456091B2 (en) 2009-08-31 2019-10-29 Abbott Diabetes Care Inc. Displays for a medical device
US9814416B2 (en) 2009-08-31 2017-11-14 Abbott Diabetes Care Inc. Displays for a medical device
US10918342B1 (en) 2009-08-31 2021-02-16 Abbott Diabetes Care Inc. Displays for a medical device
US10772572B2 (en) 2009-08-31 2020-09-15 Abbott Diabetes Care Inc. Displays for a medical device
US11202586B2 (en) 2009-08-31 2021-12-21 Abbott Diabetes Care Inc. Displays for a medical device
US9549694B2 (en) 2009-08-31 2017-01-24 Abbott Diabetes Care Inc. Displays for a medical device
US11241175B2 (en) 2009-08-31 2022-02-08 Abbott Diabetes Care Inc. Displays for a medical device
US11730429B2 (en) 2009-08-31 2023-08-22 Abbott Diabetes Care Inc. Displays for a medical device
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US11478173B2 (en) 2010-06-29 2022-10-25 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US11213226B2 (en) 2010-10-07 2022-01-04 Abbott Diabetes Care Inc. Analyte monitoring devices and methods
US10555695B2 (en) 2011-04-15 2020-02-11 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10682084B2 (en) 2011-04-15 2020-06-16 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10835162B2 (en) 2011-04-15 2020-11-17 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10561354B2 (en) 2011-04-15 2020-02-18 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10610141B2 (en) 2011-04-15 2020-04-07 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10624568B2 (en) 2011-04-15 2020-04-21 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10722162B2 (en) 2011-04-15 2020-07-28 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US11406331B2 (en) 2011-10-31 2022-08-09 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9622691B2 (en) 2011-10-31 2017-04-18 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9913619B2 (en) 2011-10-31 2018-03-13 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US10939859B2 (en) 2011-11-23 2021-03-09 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9743872B2 (en) 2011-11-23 2017-08-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9289179B2 (en) 2011-11-23 2016-03-22 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US10136847B2 (en) 2011-11-23 2018-11-27 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US10082493B2 (en) 2011-11-25 2018-09-25 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US11391723B2 (en) 2011-11-25 2022-07-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US10345291B2 (en) 2012-08-30 2019-07-09 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10942164B2 (en) 2012-08-30 2021-03-09 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10656139B2 (en) 2012-08-30 2020-05-19 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
EP2901153A4 (en) * 2012-09-26 2016-04-27 Abbott Diabetes Care Inc Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US11896371B2 (en) 2012-09-26 2024-02-13 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9907492B2 (en) 2012-09-26 2018-03-06 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
WO2014052136A1 (en) 2012-09-26 2014-04-03 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US10842420B2 (en) 2012-09-26 2020-11-24 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US10188334B2 (en) 2012-10-30 2019-01-29 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US9801577B2 (en) 2012-10-30 2017-10-31 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US10874336B2 (en) 2013-03-15 2020-12-29 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US10076285B2 (en) 2013-03-15 2018-09-18 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
US11717225B2 (en) 2014-03-30 2023-08-08 Abbott Diabetes Care Inc. Method and apparatus for determining meal start and peak events in analyte monitoring systems
US11553883B2 (en) 2015-07-10 2023-01-17 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
US10346228B2 (en) * 2017-07-12 2019-07-09 Siemens Aktiengesellschaft Method and system for deviation detection in sensor datasets
US11706876B2 (en) 2017-10-24 2023-07-18 Dexcom, Inc. Pre-connected analyte sensors
US11382540B2 (en) 2017-10-24 2022-07-12 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors

Also Published As

Publication number Publication date
US20140136145A1 (en) 2014-05-15
US8635046B2 (en) 2014-01-21

Similar Documents

Publication Publication Date Title
US8635046B2 (en) Method and system for evaluating analyte sensor response characteristics
US20230024262A1 (en) Methods, devices, and systems for physiological parameter analysis
Davidson et al. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio
US20230074956A1 (en) Method and system for providing basal profile modification in analyte monitoring and management systems
US20190051410A1 (en) Glycemic risk determination based on variability of glucose levels
US11096611B2 (en) Method for providing a signal quality degree associated with an analyte value measured in a continuous monitoring system
US10194839B2 (en) Method and device for assessment of a series of glucose concentration values of a body fluid of a diabetic for adjustment of insulin dosing
Patel et al. Activity monitoring and energy expenditure in COPD patients: a validation study
EP2988671B1 (en) Diabetes management system with a medical device
CN101088469B (en) Diabetes management methods and systems
US8589106B2 (en) Calibration of a handheld diabetes managing device that receives data from a continuous glucose monitor
EP2174248B1 (en) A method system and device for assessing insulin sensitivity
AU2019368318B2 (en) Methods, devices, and systems for physiological parameter analysis
US9092553B2 (en) Method and system for calculating daily weighted averages of glucose measurements (or derived quantities) with time based-weights
Buckingham et al. CGM-measured glucose values have a strong correlation with C-peptide, HbA 1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes
US10791969B2 (en) Method and system for method for determining a blood glucose level for a patient
CN109069003A (en) Controller gain based on probability
Mariani et al. Continuous glucose monitoring: a perspective on its past, present, and future applications for diabetes management
Vettoretti et al. Modeling the error of factory-calibrated continuous glucose monitoring sensors: application to Dexcom G6 sensor data
US20230061350A1 (en) Methods, devices, and systems for adjusting laboratory hba1c values
WO2023151213A1 (en) Analyte concentration data generation method and apparatus, and system for monitoring analyte concentration
JP6920714B2 (en) Health management device
WO2016008997A1 (en) A method and a device for determining a body fluid glucose level of a patient, and a computer program product
Bonomo et al. Real-time continuous glucose monitoring in adult outpatients
Randløv et al. Short term blood glucose measurements may be severely biased

Legal Events

Date Code Title Description
AS Assignment

Owner name: ABBOTT DIABETES CARE INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BUDIMAN, ERWIN SATRYA;REEL/FRAME:028422/0983

Effective date: 20120405

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8